Dara are available at <https://doi.org/10.6084/m9.figshare.7674092>.

Introduction {#sec006}
============

Headaches are a common problem, world-wide. The two most common types of headaches are migraine and tension-type. Migraines have a prevalence of 6--8% \[[@pone.0212785.ref001]--[@pone.0212785.ref009]\], and cause significant disability \[[@pone.0212785.ref010]--[@pone.0212785.ref013]\], even during periods between attacks \[[@pone.0212785.ref014]\]. Migraines are responsible for \$1 billion in medical costs and \$16 billion in lost productivity per year \[[@pone.0212785.ref015];[@pone.0212785.ref016]\] in the US alone. While episodic migraine is more common than chronic migraine, chronic migraine has greater disability as well as financial and occupational consequences \[8;9\] and has received much greater research attention \[[@pone.0212785.ref017]\].

Tension-type headache is more common than migraine; up to 90% of adults experience one at some time in their life \[[@pone.0212785.ref018]--[@pone.0212785.ref022]\]. In any given month, a tension-type headache occurs in 46% of adults \[[@pone.0212785.ref022]\]. Most tension-type headaches are managed with over the counter medications, consequently most do not seek medical attention. However, tension-type headache reduces the quality of life \[[@pone.0212785.ref023]\], results in up to a fifth of all missed work days \[[@pone.0212785.ref024]\], and costs EUR 21 billion annually in Europe \[[@pone.0212785.ref025]\].

There are several options available for preventing migraines including alpha antagonists, antiepileptics \[[@pone.0212785.ref026]\], beta-blockers \[[@pone.0212785.ref027]\], botulinum toxin-A \[[@pone.0212785.ref028]\], calcium channel blockers \[[@pone.0212785.ref029]\], flunarizine \[[@pone.0212785.ref017]\], pizotifen \[[@pone.0212785.ref017]\], serotonin agonists \[[@pone.0212785.ref030]\], serotonin reuptake inhibitors (SSRIs) \[[@pone.0212785.ref031]\] and tricyclic antidepressants (TCAs) \[[@pone.0212785.ref032]\]. Nearly half of males and a third of females who are candidates for prophylactic therapy do not receive it \[[@pone.0212785.ref033]\]. Selection of prophylactic treatment is tailored on individual patient characteristics, costs, perceived efficacy of the intervention and side effects of the available options.

The 2012 American Academy of Neurology guideline recommends beta-blockers, specifically propranolol and metoprolol, as first line therapy for preventing migraines \[[@pone.0212785.ref034]\]. Specific medications commonly used in prophylaxis has not been well described. In Europe, commonly prescribed prophylactic agents include antiepileptics, beta-blockers, flunarizine, pizotifen and TCAs \[[@pone.0212785.ref035]\]. Other studies found that specialists are twice as likely to prescribe antiepileptics than primary care providers \[[@pone.0212785.ref036]\], that treatment persistence is low \[[@pone.0212785.ref037]\] and that use of prophylactic medications has increased \[[@pone.0212785.ref038]\], though none of these three characterized the specific medications used.

The purpose of this study is to assess the efficacy of beta-blockers in the prophylaxis of migraine and tension-type headache. Two previous systematic reviews focused on the use of beta-blockers in migraine headaches, both are more than 15 years old \[[@pone.0212785.ref039];[@pone.0212785.ref040]\], and included limited outcomes, though both suggest benefit of beta-blockers compared to placebo. There are two more recent comparative effectiveness analyses of headache management that included beta-blockers. Shamliyan reviewed pharmacologic treatment for episodic migraine and reported that beta-blockers were effective; their outcome was 50% reduction in headaches, an outcome recommended by the International Headache Society (IHS) as a secondary outcome. They also excluded beta-blockers not approved for headaches in the U.S \[[@pone.0212785.ref041]\]. In the other meta-analysis, we found that beta-blockers were beneficial for migraine headaches, but did not differentiate between episodic and chronic migraine headaches, did not include all possible outcomes and did not examine beta-blockers for management of tension-type headache \[[@pone.0212785.ref017]\].

Methods {#sec007}
=======

This study was conducted in accordance with PRISMA guidelines ([S1 Table](#pone.0212785.s001){ref-type="supplementary-material"}. Prisma Checklist) \[[@pone.0212785.ref042]\] and was registered in PROSPERO (ID: CRD42017050335). Databases searched (without language restriction) included the Cochrane Central Register of Controlled Clinical Trials, MEDLINE, EMBASE, ISI Web of Science (SCI, SSCI, CPCI-S & CPCI-SSH), and three Chinese databases (CNKI, Wanfang and CQVIP) trough 21 August 2018 using the search strategies in supporting information ([S2 Table](#pone.0212785.s002){ref-type="supplementary-material"}. Search Strategy). Randomized controlled studies of adults that were at least four weeks in duration and used a beta-blocker in at least one study arm were included. Articles were assessed for inclusion in duplicate (JLJ, AK). Because the definition of headache has changed over time, articles were reviewed by at least two authors to determine if the headache could be reasonably classified as migraine or tension-type headache and as either frequent episodic or chronic according to the most recent IHS criteria \[[@pone.0212785.ref043]\]. IHS recommendations were followed by including only patient-reported outcomes \[[@pone.0212785.ref044]\] and including the monthly headache frequency as the primary outcome. Additional outcomes included headache index, headache days, severity, duration, quality of life, the use of acute analgesic medications, the proportion with at least 50% improvement in headaches, study withdrawal and the occurrence of adverse events. Data were abstracted in duplicate. Because of the large volume of articles, after training on a separate set of pediatric headache articles, the articles were divided among the authors with all authors serving as the primary abstractor for some articles and as the secondary reviewer, assessing for data accuracy in other articles. Disagreements resolved through consensus between the two and if consensus could not be reached, the entire group discussed and made consensual decisions.

Bias was assessed using the Cochrane risk of bias instrument \[[@pone.0212785.ref045]\] as well as the JADAD scale \[[@pone.0212785.ref046]\]. Study size was also included as a risk of bias based on sample size calculations. It was estimated that 60 subjects were required for continuous outcomes and 200 for dichotomous ones ([S3 Table](#pone.0212785.s003){ref-type="supplementary-material"}. Quality Ratings of Included Trials) based on results from our previous review of treatment of migraine headaches \[[@pone.0212785.ref017]\]. Studies with more than one arm were pooled into a single arm (if the study reported no differences between arms). For crossover trials, several approaches were used, depending on how the data was reported. For trials that provided only pooled data from both time-periods, the sample size was reduced by 50%, to avoid over-weighting the study \[[@pone.0212785.ref045]\]. For trials that provided data from both time periods separately, if there was no difference between the two-time periods, the average point estimates and variance was used, with reduction of the sample size by 50%.

The preference was to pool study outcomes in their original unit of analysis. Headache frequency was pooled as headache days per month, headache duration as hours per month, and analgesic use as number of doses per month. Since headache severity and headache index metrics varied, these outcomes were pooled using standardized mean differences \[[@pone.0212785.ref047]\]. Missing outcome variances were imputed from the reported mean, sample size, and P values \[[@pone.0212785.ref048]\]. Heterogeneity was assessed using Chi^2^ (Cochrane Q), Galbraith plots \[[@pone.0212785.ref049]\] and the I^2^ statistic \[[@pone.0212785.ref050]\]. Data were pooled at each reported time point using a random-effects model \[[@pone.0212785.ref051]\] using Stata (V15.1 College Station TX). A priori, the analytic plan was to pool data at 4, 8, 12, 16, 20 and 24 weeks. Studies that reported outcomes at different time points were combined at the closest time point available (for example, 9-week outcomes were pooled with the 8-week group). For comparative effectiveness trials with 2 or fewer studies, outcomes were reported at the last point reported. Small study effects (publication bias) was assessed using the methods of Peters \[[@pone.0212785.ref052]\] for dichotomous outcomes and Egger \[[@pone.0212785.ref053]\] for continuous outcomes if there were a sufficient number of studies. Trial sequential analysis was performed for the comparisons of propranolol to placebo for headache frequency (at 8 weeks), using the O'Brien-Fleming method of alpha-spending function to robustness of the pooled estimates against type 1 and type 2 error \[[@pone.0212785.ref054]\], using TSA software (Copenhagen, Denmark).

A network meta-analysis was performed for beta-blockers that were compared with placebo at 8 and 12 weeks using the residual maximum likelihood with a modification to the coefficients' estimated variance using the Kapp and Hartung approach \[[@pone.0212785.ref055]\] that had a minimum of 2 studies. Both 8- and 12-week results were pooled including all beta-blockers using multivariate random-effects meta-analysis using the network package in STATA \[[@pone.0212785.ref056]\].

Finally, the quality of evidence was assessed using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system to rate the quality of the evidence (GRADEPro GDT 2015) following Cochrane guidelines \[[@pone.0212785.ref045]\]. Grade assesses quality in four levels: High (further research is unlikely to change estimate of effect); Moderate (further research may impact effect estimate); Low (further research is likely to have important impact on estimate); Very low (any estimate of effect is very uncertain).

Results {#sec008}
=======

The literature search yielded 3513 unique studies after excluding duplicates. Application of inclusion and exclusion criteria ([Fig 1](#pone.0212785.g001){ref-type="fig"}) resulted in 108 randomized controlled trials \[[@pone.0212785.ref057]--[@pone.0212785.ref164]\], of which 50 had a placebo arm \[57--59;62;68;69;71;72;75;77--79;81--83;88;94--97;99;107;108;113;115;116;118;121--124;126;130;133--138;141;142;144;145;147;149;151;152;152;154;156;157;162\]. Because some placebo-controlled trials included non-placebo comparisons, there were a total of 86 comparative effectiveness arms. Nearly all trials (n = 106) focused on migraine headaches, most (n = 83) could be classified as episodic. Only 4 trials studied chronic migraines \[76;105;129;151\] and there was only 1 trial of beta-blockers for chronic tension-type headache \[[@pone.0212785.ref057]\].

![PRISMA flow chart.](pone.0212785.g001){#pone.0212785.g001}

The 108 included studies ranged from 4 to 64 weeks in duration (average: 12.9). Fifty-one were parallel in design and 57 had a crossover design. Among crossover trials, 43 were randomized, with washout periods ranging from zero to four weeks. Twenty-five different countries ([Table 1](#pone.0212785.t001){ref-type="table"}) and four languages (Chinese (n = 15), English (n = 86), German (n = 6), Polish (n = 1) were represented. The average age was 38.6 years and 77% of participants were women. Ten different beta-blockers were studied. Propranolol (n = 74) and metoprolol (n = 21) were the most commonly evaluated beta-blockers. Atenolol, nadolol, pindolol and timolol had two studies each. Several beta-blockers were evaluated in only a single trial (acebutolol, alprenolol, bisoprolol and oxprenolol). Study characteristics for included trials are provided in [Table 1](#pone.0212785.t001){ref-type="table"} and quality ratings are given in [S2 Table](#pone.0212785.s002){ref-type="supplementary-material"}.

10.1371/journal.pone.0212785.t001

###### Included trial characteristics.

![](pone.0212785.t001){#pone.0212785.t001g}

  Study, Year, Country               Comparison (mg)                                                                                Headache Type            Classification   Design      Duration (weeks)   Sample Size (dropout %)   Age    Women   Dose titrated   Rescue Medication Allowed
  ---------------------------------- ---------------------------------------------------------------------------------------------- ------------------------ ---------------- ----------- ------------------ ------------------------- ------ ------- --------------- ---------------------------
  **Acebutolol**                                                                                                                                                                                                                                                      
  Nanda, 1978, Scotland              Acebutolol (800) v. Placebo                                                                    Migraine-episodic        NS               Crossover   12                 43 (23%)                  NS     74%     Yes             Yes
  **Alprenolol**                                                                                                                                                                                                                                                      
  Ekbom, 1975, Sweden                Alprenolol (200) v. Placebo                                                                    Migraine-episodic        Ad-hoc 1962      Crossover   6                  33 (15)                   41.5   82%     No              Yes
  **Atenolol**                                                                                                                                                                                                                                                        
  Forssman, 1983, Sweden             Atenolol (100) v. Placebo                                                                      Migraine-unspecified     Ad-hoc 1962      Crossover   13                 24 (17)                   40     80%     No              Yes
  Johannsson, 1987, Sweden           Atenolol (100) v. Placebo                                                                      Migraine-episodic        Ad-hoc 1962      Crossover   12                 72 (13)                   43     70%     No              Yes
  Stensrud, 1980, Norway             Propranolol (160) v. Atenolol (100)                                                            Migraine-episodic        Ad-hoc 1962      Crossover   6                  35 (20)                   NS     69%     No              Yes
  **Bisoprolol**                                                                                                                                                                                                                                                      
  van de Ven, 1997, Europe           Bisoprolol (5) v. Bisoprolol (10) v. Placebo                                                   Migraine-episodic        IHS1988          Parallel    12                 226 (14)                  38.7   82%     No              Yes
  **Metoprolol**                                                                                                                                                                                                                                                      
  Andersson, 1983, Denmark           Metoprolol (200) v. Placebo                                                                    Migraine-episodic        WFNRG 1969       Parallel    8                  71 (13)                   39.7   85%     No              Yes
  Diener, 2001, Europe               Metoprolol (200) v. Aspirin (300)                                                              Migraine-episodic        IHS 1988         Parallel    16                 270 (15)                  39.4   81%     Yes             Yes
  Gong, 2016, China                  Metoprolol (25) + Flunarizine (5) v. Flunarizine (5)                                           Migraine-unspecified                      Parallel    12                 80 (0)                    47.5   40%     No              Yes
  Grotemeyer, 1988, Germany          Metoprolol (200) v. Flunarizine (10)                                                           Migraine-episodic        Ad hoc 1962      Crossover   7                  29 (17)                   39     79%     No              Yes
  Grotemeyer, 1990, Germany          Metoprolol (200) v. Acetylsalicyclic Acid (1500)                                               Migraine-episodic        IHS 1988         Crossover   12                 28 (NS)                   31     82%     No              Yes
  Hesse, 1994, Denmark               Metoprolol (100) v. Acupuncture                                                                Migraine-episodic        IHS 1988         Parallel    17                 85 (10)                   44.7   84%     No              Yes
  Kangasniemi, 1987, Scandinavia     Metoprolol (200) v. Placebo                                                                    Migraine-episodic        Ad-hoc 1962      Crossover   8                  77 (11)                   37.5   80%     No              Yes
  Langohr, 1985, Germany             Metoprolol (100) v. Clomipramine (100) v. Placebo                                              Migraine-episodic        Ad-hoc 1962      Crossover   4                  63 (43)                   44.4   67%     No              Yes
  Li, 2006, China                    Metoprolol (125) v. Placebo                                                                    Migraine-unspecified     IHS 1988         Parallel    12                 60 (0)                    48.5   100%    No              Yes
  Louis 1985, Europe                 Metoprolol (100) v. Clonidine (0.1)                                                            Migraine-episodic        WFNRG 1969       Crossover   8                  31 (26)                   35.5   81%     Yes             Yes
  Ma, 2011, China                    Metoprolol (50) + Flunarizine (5) v. Flunarizine (5)                                           Migraine-episodic        HIS 2004         Parallel    48                 56 (0)                    36.3   65%     No              Yes
  Schellenberg, 2008, Germany        Metoprolol (142.5) v. Nebivolol (5)                                                            Migraine-episodic        IHS 2004         Parallel    18                 30 (7)                    39     87%     Yes             Yes
  Siniatchkin, 2007, Germany         Metoprolol (200) v. Placebo                                                                    Migraine-unspecified     IHS2004          Parallel    12                 20 (0%)                   37     85%     Yes             Yes
  Sorensen 1991, Denmark             Metoprolol (200) v. Flunarizine (10)                                                           Migraine                 IHS 1988         Parallel    20                 149 (1)                   42     79%     No              Yes
  Steiner, 1988, UK                  Metoprolol Cr (100) v. Placebo                                                                 Migraine-episodic        Vahlquist 1955   Parallel    8                  59 (NS)                   37.4   76%     No              Yes
  Streng 2005, Germany               Metoprolol (200) v. Acupuncture)                                                               Migraine-episodic        IHS 1997         Parallel    12                 114 (17)                  36.6   88%     Yes             Yes
  Vilming, 1985, Sweden              Metoprolol (100) v. Pizotifen (1.5)                                                            Migraine-episodic        WFNRG 1969       Crossover   8                  35 (14)                   37.6   83%     Yes             Yes
  Worz 1992, Germany                 Metoprolol (200) v. Bisoprolol (10)                                                            Migraine-episodic        IHS1988          Crossover   12                 125 (38)                  38.5   71%     Yes             Yes
  Yang, 2006, China                  Metoprolol (90) v. Placebo                                                                     Migraine-episodic        IHS 1988         Parallel    12                 60 (0)                    48.5   100%    No              Yes
  Yang, 2016, China                  Metoprolol (95) v. Metoprolol (95) + Fluoxetine                                                Migraine-episodic        NS               Parallel    6                  120 (0)                   38.4   64%     No              Yes
  Zhou, 2015, China                  Metoprolol (95) v. Metoprolol (95) + Fluoxetine                                                Migraine-episodic        NS               Parallel    6                  112 (0)                   37.0   63%     No              Yes
  **Nadolol**                                                                                                                                                                                                                                                         
  Freitag, 1984, USA                 Nadolol (80) v. Nadolol (160) v. Placebo                                                       Migraine-unspecified     Ad-hoc 1962      Parallel    12                 32 (20)                   36.7   81%     No              Yes
  Ryan, 1982, USA                    Nadolol (80) v. Nadolol (160) v Nadolol (240) v Placebo                                        Migraine-episodic        NS               Parallel    12                 80 (1%)                   NS     78%     No              Yes
  **Oxprenolol**                                                                                                                                                                                                                                                      
  Ekbom, 1977, Sweden                Oxprenolol (240) v. Placebo                                                                    Migraine-episodic        Ad-hoc 1962      Crossover   12                 34 (12)                   41.8   76%     No              Yes
  **Pindolol**                                                                                                                                                                                                                                                        
  Ekbom, 1972, Sweden                Pindolol (7.5) v. Pindolol (15) v. Placebo                                                     Migraine-episodic        Ad-hoc 1962      Parallel    4                  30 (NS)                   33.7   87%     No              Yes
  **Pindolol + Amitriptyline**                                                                                                                                                                                                                                        
  Agius, 2013, Italy                 Pindolol (10)+ Amitriptyline (10) v. Amitriptyline (10) v. Placebo                             Tension-chronic          IHS 2004         Parallel    8                  64 (3)                    35.6   74%     No              Yes
  Streng, 2005, Germany              Metoprolol (200) v. Acupuncture                                                                Migraine-episodic        IHS 1997         Parallel    12                 114 (17)                  36.6   88%     Yes             Yes
  **Propranolol**                                                                                                                                                                                                                                                     
  Ahuja, 1985, India                 Propranolol (120) v. Placebo                                                                   Migraine-episodic        Ad-hoc 1962      Crossover   8                  26 (NS)                   NS     46%     No              NS
  al-Qassab, 1993, UK                Propranolol (80) v. Propranolol (160) v. Placebo                                               Migraine-episodic        Ad-hoc 1962      Crossover   8                  45 (33)                   36     80%     No              Yes
  Albers, 1989, USA                  Propranolol (180) v. Nifedipine (60)                                                           Migraine-episodic        Ad hoc 1962      Parallel    24                 40 (37)                   35.2   89%     Yes             Yes
  Andersson, 1981, Denmark           Propranolol (160) v. Femoxitine (400)                                                          Migraine                 NS               Crossover   24                 49 (24)                   38     69%     Yes             Yes
  Ashtari, 2008, Iran                Propranolol (80) vs. Topiramate (50)                                                           Migraine-episodic        IHS 2005         Parallel    8                  62 (3)                    30.8   82%     Yes             Yes
  Baldrati, 1983, Italy              Propranolol (80) v. Aspirin (1.9 mg/kg)                                                        Migraine-not specified   Ad hoc 1962      Crossover   12                 18 (33)                   33.3   89%     No              NS
  Behan, 1980, Scotland              Propranolol (120) v. Methysergide (3)                                                          Migraine-not specified   NS               Crossover   12                 56 (36)                   NS     66%     No              No
  Bonuso, 1998, Italy                Propranolol (80) v. Flunarizine (10)                                                           Migraine-not specified   IHS 1988         Parallel    8                  50 (16)                   32     68%     No              NS
  Bordini, 1997, Brazil              Propranolol (60) v. Flunarizine (10) v. Combo.                                                 Migraine-episodic        IHS 1988         Parallel    17                 52 (13)                   31.2   91%     No              Yes
  Borgesen, 1974, Denmark            Propranolol (120) v. Placebo                                                                   Migraine-episodic        Ad-hoc 1962      Crossover   12                 12 (33)                   37.6   83%     Yes             Yes
  Carroll, 1990, UK                  Propranolol (80) v. Propranolol (160)                                                          Migraine-episodic        Ad hoc 1962      Crossover   12                 51 (27)                   39     69%     No              Yes
  Chen, 2009, China                  Propranolol (60) + Flunarizine (10) v. Topoiramate (100)                                       Migraine-episodic        IHS 1988         Parallel    12                 82 (0)                    38.2   60%     Yes             Yes
  Dahlof, 1987, Sweden               Propranolol (120) v. Placebo                                                                   Migraine-episodic        WFNRG 1969       Crossover   4                  28 (0)                    NS     93%     No              Yes
  Diener, 1996, German               Propranolol (120) v. Cylcendalate (1200) v. Placebo                                            Migraine-episodic        IHS 1988         Parallel    12                 214 (17)                  39     78%     Yes             Yes
  Diener, 2002, Germany              Propranolol (160) v. Flunarizine (5) v. Flunarizine (10)                                       Migraine-episodic        IHS 1988         Parallel    16                 808 (18)                  38.8   63%     Yes             Yes
  Diener, 2004, Europe               Propranolol (160) v. Topiramate (100) v. Topiramate (200) v. Placebo                           Migraine-episodic        IHS 1988         Parallel    26                 575 (37)                  41     80%     Yes             Yes
  Domingues, 2009, Brazil            Propranolol (80) v. Nortriptyline (40) v. Combo.                                               Migraine-chronic         IHS 2004         Parallel    12                 76 (42)                   NS     NS      Yes             Yes
  DongXiang, 2010, China             Propranolol (90) + Amitriptyline (100) v. Amitriptyline (100)                                  Migraine-episodic        HIS 1988         Parallel    12                 310 (0)                   32.5   80%     Yes             Yes
  Formisano, 1991, Italy             Propranolol (120) v. Nimodipine (120)                                                          Migraine-episodic        IHS 1988         Parallel    16                 22 (14)                   39.2   55%     No              Yes
  Forssman, 1976, Sweden             Propranolol (240) v. Placebo                                                                   Migraine-unspecified     NS               Crossover   10                 40 (20)                   37.4   88%     No              Yes
  Gawel, 1992, Canada                Propranolol (120) v. Flunarizine (10)                                                          Migraine-episodic        WFNRG 1970       Parallel    16                 94 (19)                   35.9   89%     Yes             Yes
  Gerber, 1991, Germany              Propranolol (120) v. Metoprolol (150) v. Nifedipine (30)                                       Migraine-episodic        IHS 1988         Parallel    12                 58 (NS)                   42.4   73%     Yes             Yes
  Gerber, 1995, Germany              Propranolol (120/160) v. Cyclandelate (1200/1600)                                              Migraine-episodic        IHS 1988         Parallel    8                  84 (26)                   40.9   90%     No              Yes
  Ghobadi, 2013, Iran                Propranolol (120) v. Nimodipine (30)                                                           Migraine                 IHS 2004         Parallel    24                 102 (2)                   47     83%     No              Yes
  Grotemeyer, 1987, German           Propranolol (120) v. Placebo                                                                   Migraine-episodic        Ad-hoc 1962      Crossover   12                 30 (20)                   36     73%     No              Yes
  Havanka-Kannianen, 1988, Finland   Propranolol (80) v. Propranolol (160)                                                          Migraine-episodic        Ad-hoc 1962      Crossover   12                 48 (13)                   37.7   81%     No              Yes
  Hedman, 1986, Denmark              Propranolol (80) v. Metoprolol (100)                                                           Migraine-episodic        WFNRG 1970       Crossover   4                  12 (0)                    40     67%     NS              Yes
  Holdorff, 1977, Germany            Propranolol (120) v. Placebo                                                                   Migraine-episodic        Ad-hoc 1962      Parallel    12                 53 (30)                   NS     NS      No              Yes
  Holroyd, 2010, USA                 Propranolol/Nadolol v. Propranolol/Nadolol + Behavior Therapy v. Behavior therapy v. Placebo   Migraine-episodic        IHS 1988         Parallel    64                 232 (51)                  38.2   79%     Yes             Yes
  Jin, 2001, China                   Propranolol (30) + Flunarizine (10) v. Diazepam (30) + Nimodipine (60)                         Migraine                 NS               Parallel    24                 84 (0)                    NS     75%     No              Yes
  Johnson, 1986, New Zealand         Propranolol (240) Mefenamic Acid (1500) v. Placebo                                             Migraine-episodic        NS               Crossover   12                 29 (41)                   42     69%     No              Yes
  Kangasniemi 1983, Finland          Propranolol (160) v. Femoxetine (400)                                                          Migraine-episodic        NS               Crossover   12                 29 (11)                   37     86%     No              Yes
  Kangasniemi 1984, Finland          Propranolol (240) v. Metoprolol (200)                                                          Migraine-episodic        WFNRG 1970       Crossover   8                  36 (6)                    33.8   89%     No              Yes
  Kaniecki, 1997, USA                Propranolol (240) v. Divalproex (1500)                                                         Migraine-episodic        IHS 1988         Crossover   12                 37 (14)                   NS     81%     Yes             Yes
  Kass, 1980, Norway                 Propranolol (160) v. Clonidine (0.1)                                                           Migraine-unspecified     WFNRG 1970       Crossover   16                 23 (9)                    39.7   30%     No              Yes
  Kaushik, 2005, India               Propranolol (80) v. Biofeedback                                                                Migraine-episodic        IHS 1988         Parallel    24                 192 (13)                  NS     69%     No              Yes
  Ke, 2003, China                    Propranolol (30) v. Propranolol (30) + Flunarizine (5) v. Flunarizine (5)                      Migraine-chronic         IHS 1988         Parallel    8                  121 (0)                   31     74%     No              Yes
  Kjaersgard 1994, Denmark           Propranolol (120) v. Tolfenamic Acid (300)                                                     Migraine-unspecified     IHS 1988         Crossover   12                 76 (26)                   43.3   79%     No              Yes
  Klapper, 1994,USA                  Propranolol (140) v. Divalproex (1100)                                                         Migraine-unspecified     IHS 1988         Crossover   8                  24 (50)                   NS     NS      Yes             Unclear
  Kozubski, 1995, Poland             Propranolol (160) Valproaic Acid (1500)                                                        Migraine-unspecified     IHS 1988         Crossover   10                 35 (NS)                   NS     100%    Yes             NS
  Kuritzky, 1987, Israel             Propranolol (160) v. Placebo                                                                   Migraine-episodic        NS               Crossover   8                  38 (18)                   NS     NS      No              Yes
  Li, 2002, China                    Propranolol (30) v. Flunarizine (5)                                                            Migraine-Episodic        IHS, 1988        Parallel    4                  126 (0)                   38.7   60%     No              Yes
  Li, 2004, China                    Propranolol (60) v. Valproate (.45 mg/kg)                                                      Migraine-Episodic        NS               Parallel    36                 40 (0)                    NS     NS      No              NS
  Lucking, 1988, Germany             Propranolol (120) v. Flunarizine (10)                                                          Migraine-episodic        NS               Parallel    16                 521 (NS)                  42     80%     No              Yes
  Maissen, 1991, Germany             Propranolol (120) v. 5-Hydroxytryptophan (300)                                                 Migraine-episodic        NS               Parallel    16                 39 (18)                   39.4   67%     Yes             Yes
  Malvea, 1973, USA                  Propranolol (NS) v. Placebo                                                                    Migraine-episodic        NS               Crossover   6                  31 (6)                    NS     87%     Yes             Yes
  Mathew, 1980, USA                  Propranolol (160) v. Placebo v. Amitriptyline (75) v. Biofedback                               Mixed- headaches         NS               Parallel    24                 340 (20)                  35.5   94%     Yes             Yes
  Mikkelsen, 1986, Denmark           Propranolol (120) v. Tolfenamic Acid (300) v. Placebo                                          Migraine-episodic        Ad-hoc 1962      Crossover   12                 31 (21)                   39.4   84%     No              Yes
  Nadelmann, 1986, USA               Propranolol (320) v. Placebo                                                                   Migraine-unspecified     Ad-hoc 1962      Crossover   12                 57 (39)                   NS     86%     No              Yes
  Nair, 1975, India                  Propranolol (80) v. Placebo                                                                    Migraine-episodic        NS               Crossover   8                  20 (0)                    27.3   50%     No              No
  Nambiar, 2011, India               Propranolol (80) v. Riboflavin (100)                                                           Migraine-episodic        IHS 1988         Parallel    24                 100 (NS)                  31     55%     Yes             Yes
  Palferman, 1983, UK                Propranolol (120) v. Placebo                                                                   Migraine-unspecified     NS               Crossover   8                  10 (38)                   41.4   80%     No              Yes
  Olerud, 1986, Sweden               Propranolol (80) v. Nadolol (80)                                                               Migraine-episodic        NS               Parallel    24                 28(NS)                    NS     79%     No              Yes
  Pita, 1977, Spain                  Propranolol (160) v. Placebo                                                                   Migraine-episodic        Ad-hoc 1962      Crossover   8                  9 (0)                     32     78%     No              Yes
  Pradalier, 1989, Norway            Propranolol (160) v. Placebo                                                                   Migraine-episodic        IHS 1988         Parallel    12                 74 (26)                   37.4   76%     No              NS
  Ryan, 1984, USA                    Propranolol (160) v. Nadolol (80) v. Nadolol (160)                                             Migraine-episodic        NS               Parallel    12                 48 (6)                    NS     73%     No              Yes
  Sargent, 1985, USA                 Propranolol (120) v. Naproxen (1100) v. Placebo                                                Migraine-episodic        NS               Parallel    14                 149 (16)                  30     79%     Yes             Yes
  Shimell, 1990, South Africa        Propranolol (180) v. Flunarizine (10)                                                          Migraine-episodic        Ad hoc 1962      Parallel    16                 58 (2)                    34     70%     Yes             NS
  Silberstein, 2012, USA             Propranolol (240) + Topiramate (100) v. Topiramate (100)                                       Migraine-chronic         IHS 2006         Parallel    24                 191 (39)                  42     90%     Yes             Yes
  Sjaastad, 1972, Norway             Pindolol (15) v. Placebo                                                                       Migraine-episodic        NS               Crossover   4                  28 (14)                   35.3   79%     Yes             Yes
  Soyka, 1990, Germany               Propranolol (120) v. Flunarizine (10)                                                          Migraine-unspecified     NS               Parallel    16                 434                       42     82%     Yes             Yes
  Standnes, 1982, Norway             Propranolol (80) v. Timolol (10) v. Placebo                                                    Migraine-episodic        Ad-hoc 1962      Crossover   12                 25 (28)                   41.4   80%     Yes             Yes
  Stensrud, 1976, Norway             Propranolol (160) v. Placebo                                                                   Migraine-episodic        Ad-hoc 1962      Crossover   4                  20 (5)                    43.5   70%     No              Yes
  Stensrud, 1980, Norway             Propranolol (80) v. Atenolol (50) v. Placebo                                                   Migraine-episodic        Ad-hoc 1962      Crossover   6                  35 (20)                   NS     69%     No              Yes
  Stovner, 2014, Norway              Propranolol (160) v. Candesartan (16) v. Placebo                                               Migraine-episodic        NS               Crossover   12                 72 (15)                   37     82%     Yes             Yes
  Sudilovsky, 1987, USA              Propranolol (160) v. Nadolol (80) v. Nadolol (160)                                             Migraine-episodic        Ad hoc 1962      Parallel    12                 140 (30)                  39.3   76%     Yes             Yes
  Tfelt-Hansen, 1984, Scandinavia    Propranolol (160) v. Timolol (20) v. Placebo                                                   Migraine-episodic        Ad-hoc 1962      Crossover   12                 96 (28)                   39.5   74%     No              Yes
  Weber, 1971, USA                   Propranolol (20) v. Placebo                                                                    Migraine-unspecified     Ad-hoc 1962      Crossover   12                 25 (24)                   40.6   52%     No              Yes
  Wideroe, 1974, Norway              Propranolol (160) v. Placebo                                                                   Migraine-episodic        Ad-hoc 1962      Crossover   12                 30 (13)                   40     90%     No              Yes
  Wen, 2016, China                   Propranolol (30) v. Flunarizine (10)                                                           Migraine Episodic        NS               Parallel    8                  100 (0)                   25.6   65%     No              Yes
  Yuan, 2005, China                  Propranolol (120) v. Topiramate (150)                                                          Migraine-unspecified     IHS 1988         Parallel    12                 67 (0)                    29.9   64%     Yes             No
  Zhu, 2005, China                   Propranolol (30) v. Flunarizine (10)                                                           Migraine-unspecified     IHS 1988         Parallel    8                  90 (0)                    28.1   73%     No              No
  Ziegler, 1993, USA                 Propranolol (240) v. Amitriptyline (150) v. Placebo                                            Migraine-episodic        NS               Crossover   10                 54 (44)                   38     73%     Yes             Yes
  **Timolol**                                                                                                                                                                                                                                                         
  Briggs, 1979, UK                   Timolol (20) v. Placebo                                                                        Migraine-episodic        Ad-hoc 1962      Crossover   6                  14 (7)                    NS     71%     No              Yes
  Stellar, 1984, USA                 Timolol (30) v. Placebo                                                                        Migraine-episodic        Ad-hoc 1962      Crossover   8                  107 (12)                  43     72%     No              Yes

NS: Not Stated

Studies had a number of common quality problems ([S3 Table](#pone.0212785.s003){ref-type="supplementary-material"}) including high drop-out rates (16.1%, range 0--51%), lack of intention to treat analysis (76%), inadequate sequence generation (83%), lack of evidence of concealed allocation (90%) and inadequate blinding (60%). Twenty-three studies assessed compliance (21%). Fifty-one (47%) studies reported all collected outcomes. Sixteen trials (15%) were sponsored by industry. All comparisons that had only a single study were graded as low-quality evidence.

Episodic migraines {#sec009}
------------------

The primary outcome was headaches per month. Outcomes from placebo-controlled trials for all beta-blockers and time-points are provided in Tables [2](#pone.0212785.t002){ref-type="table"}--[3](#pone.0212785.t003){ref-type="table"}. Outcomes at 8 weeks was the most commonly reported time point. Among patients with episodic migraines ([Table 2](#pone.0212785.t002){ref-type="table"}), the average number of headaches at baseline was 4.9 headaches/month (95% CI: 4.4--5.4). The best studied beta-blocker was propranolol, which was more effective than placebo at 8 and 12 weeks (8 weeks: -1.5 ha/month, 95% CI: -2.3 to -0.65); 12 weeks: -1.2 ha/month, 95% CI: -1.8 to -0.60, [Fig 2](#pone.0212785.g002){ref-type="fig"}). Propranolol outcomes at 8 and 12 weeks were both graded as high-quality evidence. TSA analysis of propranolol vs. placebo for headache frequency demonstrated that it is unlikely that these results are due to a Type 1 error ([Fig 3](#pone.0212785.g003){ref-type="fig"}). Other beta-blockers that were more effective than placebo at 8 weeks ([Fig 4](#pone.0212785.g004){ref-type="fig"}) included bisoprolol (-0.70 ha/month, 95% CI: -1.4 to -0.05, low quality), metoprolol (-0.86 ha/month, 95% CI: -1.4 to -0.34, moderate quality) and timolol (-0.77 ha/month, 95% CI: -1.4 to -0.12, moderate quality). The remaining beta-blockers, in single trials did not significantly reduce headache frequency ([Fig 3](#pone.0212785.g003){ref-type="fig"}). There was a similar pattern at twelve weeks.

![Headaches per month, Propranolol v. Placebo.](pone.0212785.g002){#pone.0212785.g002}

![Trial Sequential Analysis (Propranolol v. Placebo).](pone.0212785.g003){#pone.0212785.g003}

![Headaches per month, other Beta Blockers v Placebo.](pone.0212785.g004){#pone.0212785.g004}

10.1371/journal.pone.0212785.t002

###### Placebo controlled primary outcome (headache frequency per month).

![](pone.0212785.t002){#pone.0212785.t002g}

  Episodic Migraines                                                                                                                                              
  ----------------------------------------------------------------------------------------------------- ------------------------ -------------------------------- ----------
  **Acebutolol** (HA frequency at baseline: 4.8 headaches/month (95% CI: -0.64 to 8.9))                                                                           
  Baseline Frequency                                                                                    0.00 (-0.14 to 0.14)     ---                              Low
  4 weeks                                                                                               -0.20 (-0.38 to -0.02)   ---                              
  8 weeks                                                                                               -0.50 (-1.6 to 0.63)     ---                              
  12 weeks                                                                                              -0.6 (-1.7 to 0.53)      ---                              
  **Alprenolol**                                                                                                                                                  
  8 weeks                                                                                               -0.80 (-1.9 to 0.31)     ---                              Low
  **Atenolol**                                                                                                                                                    
  12 weeks                                                                                              -1.7 (-3.0 to -0.32)     ---                              Low
  **Bisoprolol** (HA frequency at baseline: 5.5 headaches/month (95% CI: 2.7 to 8.3))                                                                             
  Baseline                                                                                                                                                        Low
  5 mg                                                                                                  0.40 (-0.19 to 0.99)     ---                              
  10 mg                                                                                                 0.20 (-0.40 to 0.80)     ---                              
  4 weeks                                                                                                                                                         
  5 mg                                                                                                  -0.40 (-1.1 to 0.29)     ---                              
  10 mg                                                                                                 -0.40 (-1.1 to 0.34)     ---                              
  8 weeks                                                                                                                                                         
  5 mg                                                                                                  -0.50 (-1.2 to 0.25)     ---                              
  10 mg                                                                                                 -0.70 (-1.4 to -0.05)    ---                              
  12 weeks                                                                                                                                                        
  5 mg                                                                                                  -0.90 (-1.53 to -0.27)   ---                              
  10 mg                                                                                                 -0.90 (-1.6 to -0.24)    ---                              
  **Metoprolol** (HA frequency at baseline: 3.9 headaches/month (3.1 to 4.7))                                                                                     
  Baseline                                                                                              -0.04 (-0.49 to 0.41)    Q = 3.68, df = 3, I^2^ = 18.5%   Low
  4 weeks                                                                                               -0.91 (-2.6 to 0.82)     ---                              ---
  8 weeks                                                                                               -0.86(-1.4 to -0.34)     Q = 3.07, df = 2, I^2^ = 34.8%   Moderate
  12 weeks                                                                                              -0.90 (-2.2 to 0.41)     ---                              Low
  **Nadolol** (HA frequency at baseline: 6.7 headaches/month (3.4 to 9.9)                                                                                         
  Baseline                                                                                              0.22 (-1.8 to 2.3)       ---                              Low
  4 weeks                                                                                               1.1 (-0.98 to 3.2)       ---                              
  8 weeks                                                                                               -0.86 (-2.9 to 1.3)      ---                              
  12 weeks                                                                                              -0.96 (-3.1 to 1.2)      ---                              
  **Oxprenolol**                                                                                                                                                  
  8 weeks                                                                                               -0.80 (-3.9 to 2.3)      ---                              Low
  **Propranolol** (HA frequency at baseline: 4.8 headaches/month (4.3 to 5.3))---                                                                                 
  Baseline                                                                                              -0.04 (-0.28 to 0.20)    Q = 0.83, df = 10, I^2^ = 0.0%   High
  4 weeks                                                                                               -1.1 (-1.8 to -0.43)     Q = 0.0, df = 1, I2 = 0.0%       Moderate
  8 weeks                                                                                               -1.5 (-2.3 to -0.65)     Q = 11.37, df = 7, I2 = 38.4%    High
  12 weeks                                                                                              -1.2 (-1.8 to-0.60)      Q = 35.29, df = 8, I2 = 77.3%    High
  16 weeks                                                                                              -1.2 (-2.4 to -0.01)     ---                              Low
  20 weeks                                                                                              -0.9 (-1.8 to -0.02)     ---                              Low
  24 weeks                                                                                              -0.9 (-1.5 to -0.32)     ---                              Low
  40 weeks                                                                                              -0.3 (-0.9 to 0.34)      ---                              Low
  64 weeks                                                                                              -0.3 (-0.98 to 0.38)     ---                              Low
  **Timolol** (HA frequency at baseline: 4.8 headaches/month (95% CI: -0.64 to 8.9))                                                                              
  Baseline                                                                                              (-0.45 to 0.45)          Q = 0.0, df = 2, I2 = 0.0%       Moderate
  8 weeks                                                                                               -0.77 (-1.4 to -0.12)    Q = 1.03, df = 1, I^2^ = 3.2%    
  12 weeks                                                                                              -1.53 (-2.5 to -0.78)    Q = 0.16, df = 1, I^2^ = 0.0%    
  **Migraine-Chronic**                                                                                                                                            
  **Propranolol**                                                                                                                                                 
  8 weeks                                                                                               -2.1 (-5.5 to 1.3)       ---                              Low
  **Chronic Tension-type HA**                                                                                                                                     
  **Pindolol+ Amitriptyline** (HA frequency at baseline: 20.0 headaches/month (95% CI: 18.5 to 29.5))                                                             
  Baseline                                                                                              1.4 (-2.2 to 5.0)        ---                              Low
  4 weeks                                                                                               -7.8 (-13.9 to -1.5)     ---                              
  8 weeks                                                                                               -11.2 (-16.7 to -5.5)    ---                              
  **Propranolol** (HA frequency at baseline: 20.0 headaches/month (95% CI: 18.5 to 29.5))                                                                         
  Baseline                                                                                              (-8.1 to 8.1)            ---                              Low
  8 weeks                                                                                               -4.5 (-8.2 to -0.82)     ---                              

10.1371/journal.pone.0212785.t003

###### Secondary outcomes of placebo controlled trials.

![](pone.0212785.t003){#pone.0212785.t003g}

  --------------------------------------------------------------------------- ------------------------------------------- --------------------------------- -------------------------
  **Episodic Migraines**                                                                                                                                    

  **50% Improvement in Headaches**                                                                                                                          

  **Beta-blocker**                                                            **RR (95% CI)/NNT**                         **Heterogeneity**                 **Quality of Evidence**

  Atenolol                                                                    1.8 (1.0 to 3.2)/6.3 (3.2--33.3)            ---                               Low

  Metoprolol                                                                  1.7 (1.0 to 2.9)/5 (3.5--8.8)               Q = 8.85, df = 3, I^2^ = 66.1%    Moderate

  Nadolol                                                                     5.1 (0.32 to 81.3)/3.7 (1.9--90.9)          ---                               Low

  Propranolol                                                                 1.4 (1.1 to 1.8)/5.3 (3.4--11.4)            Q = 26.1, df = 10, I^2^ = 59.5%   High

  Timolol                                                                     1.8 (1.4 to 2.3)/4.5 (3.1--7.7)             Q = 0.86, df = 2, I2 = 0.0%       Moderate

  **Analgesic Medication Consumption**                                                                                                                      

  **Beta-blocker**\                                                           **Weighted Mean Difference (95% CI)**       **Heterogeneity**                 
  **Time point**                                                                                                                                            

  **Metoprolol** (Baseline analgesic doses/month: 6.7, 95% CI: 3.4 to 10.0)                                                                                 

  Baseline                                                                    -0.17 (-1.4 to 1.1)                         Q = 0.5, df = 3, I^2^ = 0.0%      High

  4 weeks                                                                     -2.4 (-4.9 to 0.08)                         ---                               Low

  8 weeks                                                                     -4.0 (-7.5 to -0.48)                        Q = 3.49, df = 2, I^2^ = 42.8%    Moderate

  **Propranolol** (Baseline analgesic doses/month 11.1, 95% CI: 4.8--17.4)                                                                                  

  Baseline                                                                    0.0 (-1.9 to 1.9)                           Q = 0.26, df = 7, I^2^ = 0.00     High

  4 weeks                                                                     -6.0 (-11.8 to -0.12)                       ---                               Low

  8 weeks                                                                     -2.9 (-25.9 to 20.2)                        ---                               Low

  12 weeks                                                                    -2.1 (-3.2 to -0.95)                        Q = 33.82, df = 5, I^2^ = 85.2%   High

  **Headache Index**                                                                                                                                        

  **Beta-blocker**\                                                           **Standardized Mean Difference (95% CI)**   **Heterogeneity**                 
  **Time point**                                                                                                                                            

  **Alprenolol**                                                                                                                                            

  8 weeks                                                                     0.05 (-0.47 to 0.58)                        ---                               Low

  **Atenolol**                                                                                                                                              

  8 weeks                                                                     -0.62 (-1.2 to -0.004)                      ---                               Low

  12 weeks                                                                    -0.65 (-1.3 to -0.01)                       ---                               

  **Metoprolol**                                                                                                                                            

  Baseline                                                                    0.12 (-0.22 to 0.47)                        Q = 0.07, df = 1, I^2^ = 0.0%     Moderate

  8 weeks                                                                     -0.42 (-0.77 to -0.07)                      Q = 0.98, df = 1, I^2^ = 0.0%     

  **Nadolol**                                                                                                                                               

  Baseline                                                                    0.12 (-0.24 to 0.48)                        ---                               Low

  4 weeks                                                                     0.16 (-0.20 to 0.52)                        ---                               

  8 weeks                                                                     -0.14 (-0.50 to 0.23)                       ---                               

  12 weeks                                                                    -0.27 (-0.64 to 0.10)                       ---                               

  **Oxprenolol**                                                                                                                                            

  4 weeks                                                                     -1.7 (-2.3 to -1.1)                         ---                               Low

  8 weeks                                                                     -0.42 (-0.09 to 0.93)                       ---                               

  **Pindolol**                                                                                                                                              

  Baseline                                                                    0.14 (-0.52 to 0.80)                        ---                               Low

  4 weeks                                                                     0.27 (-0.40 to 0.93)                        ---                               

  **Propranolol**                                                                                                                                           

  0 weeks                                                                     -0.03 (-0.23 to 0.16)                       Q = 6.24, df = 6, I^2^ = 19.9%    High

  4 weeks                                                                     -0.66 (-1.3 to -0.01)                       ---                               Low

  8 weeks                                                                     -0.48 (-0.75 to -0.22)                      Q = 2.54, df = 4, I^2^ = 0.0%     High

  12 weeks                                                                    -0.41 (-0.65 to -0.17)                      Q = 2.56, df = 3, I^2^ = 0.0%     High

  **Timolol**                                                                                                                                               

  Baseline                                                                    0.0 (-0.31 to 0.31)                         ---                               Low

  12 weeks                                                                    -0.53 (-0.84 to -0.21)                      ---                               

  **Headache Severity**                                                                                                                                     

  **Metoprolol**                                                                                                                                            

  Baseline                                                                    -0.06 (-0.33 to 0.21)                       Q = 1.65, df = 2, I^2^ = 0.0%     High

  8 weeks                                                                     -0.53 (-0.71 to -0.14)                      Q = 0.15, df = 1, I^2^ = 0.0%     Moderate

  **Propranolol**                                                                                                                                           

  Baseline                                                                    (-0.21 to 0.21)                             Q = 0.00, df = 2, I^2^ = 0.0%     High

  8 weeks                                                                     -0.51 (-0.76 to -0.26)                      Q = 1.73, df = 4, I^2^ = 0.0%     

  12 weeks                                                                    0.18 (-0.30 to 0.01)                        Q = 3.70, df = 2, I^2^ = 46.0%    

  **Timolol**                                                                                                                                               

  Baseline                                                                    0.00 (-0.31 to 0.31)                        ---                               Low

  12 weeks                                                                    -0.35 (-0.66 to -0.04)                      ---                               

  **Headache Duration (hours)**                                                                                                                             

  **Beta-blocker**\                                                           **Weighted Mean Difference (95% CI)**       **Heterogeneity**                 
  **Time point**                                                                                                                                            

  **Bisoprolol (baseline duration 20.6 hours, 95% CI: 0 to 46.7)**                                                                                          

  Baseline                                                                    -3.9 (-8.6 to 0.77)                         ---                               Low

  12 weeks                                                                    -1.9 (-6.5 to 2.5)                          ---                               

  **Metoprolol (baseline duration: 11.6 hours, 95% CI: 2.6 to 20.5)**                                                                                       

  Baseline                                                                    0.06 (-1.6 to 1.7)                          ---                               Low

  4 weeks                                                                     -2.6 (-4.2 to -0.88)                        ---                               

  8 weeks                                                                     -2.0 (-3.7 to -0.26)                        ---                               

  **Propranolol (baseline duration: 28.9 hours, 95% CI: 0 to 72.3)**                                                                                        

  Baseline                                                                    0.22 (-2.4 to 2.8)                          Q = 0.99, df = 2, I^2^ = 0.0%     High

  8 weeks                                                                     -6.1 (-16.2 to -0.39)                       Q = 5.67, df = 2, I^2^ = 64.7%    

  12 weeks                                                                    -1.6 (-3.0 to -0.11)                        Q = 2.50, df = 4, I^2^ = 0.0%     

  **Pindolol (baseline duration: 6.6 hours, 95% CI: 0 to 23.7)**                                                                                            

  Baseline                                                                    -0.93 (-9,7 to 7.8)                         Q = 0.01, df = 1, I^2^ = 0.0%     Moderate

  4 weeks                                                                     -0.18 (-8.8 to 8.4)                         Q = 0.01, df = 1, I^2^ = 0.0%     

  **Timolol (baseline duration 9.4 hours, 95% CI: 0 to 19.8)**                                                                                              

  Baseline                                                                    (-1.3 to 1.3)                               ---                               Low

  8 weeks                                                                     -0.70 (-2.2 to 0.80)                        ---                               

  12 weeks                                                                    -0.54 (-2.7 to 1.6)                         ---                               

  **Tension-type Headache**                                                                                                                                 

  **50% improvement in Headache**                                                                                                                           

  **Beta-blocker**                                                            **RR (95% CI)**                             **Heterogeneity**                 

  Pindolol + Amitriptyline                                                    3.8 (1.5 to 9.3)                            ---                               Low

  **Headache Index**                                                                                                                                        

  **Propranolol**                                                                                                                                           

  4 weeks                                                                     -0.52 (-1.0 to -0.003)                      ---                               Low

  **Severity**                                                                                                                                              

  **Pindolol + Amitriptyline**                                                                                                                              

  Baseline                                                                    -0.29 (-0.34 to 0.91)                       ---                               Low

  8 weeks                                                                     -0.68 (-1.3 to -0.04)                       ---                               
  --------------------------------------------------------------------------- ------------------------------------------- --------------------------------- -------------------------

Among secondary outcomes, the majority of trials studied subjects with episodic migraine headaches ([Table 3](#pone.0212785.t003){ref-type="table"}). Propranolol was the most commonly studied beta-blocker. Propranolol was more likely to reduce headaches by 50% than placebo at 12 weeks (RR: 1.4, 95% CI: 1.1--1.8, NNT: 4.5, 95% CI: 2.8--12.9). Other effective beta-blockers included atenolol (RR: 1.8, 95% CI: 1.0--3.2, NNT: 6.3, 95% CI: 3.2--332.4), metoprolol (RR: 1.9, 95% CI: 1.3--2.8, NNT: 4.7, 95% CI:3.0--10.4) and timolol (RR: 1.8, 95% CI: 1.4--2.3, NNT: 4.2, 95% CI: 2.7--8.8,). At 8 weeks, metoprolol reduced analgesic medication use (-4.0 doses/month, 95% CI: -7.5 to -0.48) as did propranolol at 12 weeks (-2.1 doses/month, 95% CI: -3.2 to -0.95). The headache index was modestly reduced by a number of different beta-blockers including atenolol (SMD: -0.62, 95% CI: -1.2 to -0.004), metoprolol (SMD: -0.42, 95% CI: -0.77 to -0.07), propranolol (SMD: -0.48, 95% CI: -0.75 to -0.22) and timolol (SMD: -0.53, 95% CI: -0.84 to -0.21). At 8 weeks, headache severity was modestly reduced by both metoprolol (SMD: -0.53, 95% CI: -0.71 to -0.14) and propranolol (SMD: -0.51, 95% CI: -0.76 to -0.26). Headache duration was reduced by metoprolol (-2.0 hours, 95% CI: -3.7 to -0.26) and propranolol (-6.1 hours, 95% CI: -16.2 to -0.39).

### Network meta-analysis {#sec010}

For the primary outcome, headache frequency, the network meta-analysis found no difference at 8 weeks (p = 0.27) in effectiveness in comparisons between propranolol (n = 9) compared to bisoprolol (n = 2), metoprolol (n = 3) and nadolol (n = 3). Similarly, at 12 weeks, there was no difference (p = 0.84) n effectiveness in comparisons between propranolol (n = 9) compared to bisoprolol (n = 2), nadolol (n = 3) and timolol (n = 2). The 8- and 12-week analysis confirmed this lack of difference between all beta-blockers ([Fig 5](#pone.0212785.g005){ref-type="fig"}), including those with single trials ([Fig 6](#pone.0212785.g006){ref-type="fig"})

![Network meta-analysis map.](pone.0212785.g005){#pone.0212785.g005}

![Results of network meta-analysis comparisons.](pone.0212785.g006){#pone.0212785.g006}

### Comparative effectiveness trials {#sec011}

There were 83 randomized trials that included at least one comparison to a non-placebo treatment. Propranolol was the most commonly compared beta-blocker (n = 72, 87%). Propranolol was compared to pharmacologic interventions in 50 trials. Eleven comparisons that were from single trials (5-hydroxytryptophan, aspirin, atenolol, candesartan, clonidine, cyclandelate, mefenamic acid, naproxen, nifedipine, nimodipine, nortriptyline, pindolol, riboflavin). Comparisons with more than one study included: amitriptyline (n = 2), femoxetine (n = 2), flunarizine (n = 11), metoprolol (n = 4), nadolol (n = 3), nimodipine (n = 2), timolol (n = 2) tofenamic acid (n = 2), topiramate (n = 3) and valproate (n = 3). Several combinations were tested including propranolol + amitriptyline vs. amitriptyline (n = 1), and propranolol + flunarizine was compared to flunarizine. Propranolol combined with topiramate was compared with topiramate alone. Nonpharmacologic interventions were compared to propranolol in three trials (acupuncture, behavioral management, biofeedback). Metoprolol was assessed in 14 trials, 8 were comparisons with pharmacologic interventions (aspirin, bisoprolol, clomipramine, clonidine, flunarizine, nebivolol, pizotifen) and one with nonpharmacologic (acupuncture). Metoprolol was compared to a combination of metoprolol and fluoxetine in 2 trials and the combination of metoprolol and flunarizine was compared to flunarizine alone in 2 trials.

The primary outcome comparison (headache frequency) is provided in [Table 4](#pone.0212785.t004){ref-type="table"}, and secondary outcomes are in [Table 5](#pone.0212785.t005){ref-type="table"}. The majority of comparisons were single trials, making definitive conclusions difficult. Metoprolol, but not propranolol, was more effective than aspirin. Metoprolol was more effective than clomipramine, though comparable to acupuncture, bisoprolol, clonidine, flunarizine, nebivolol and pizotifen. Adding fluoxetine to metoprolol or flunarizine to either propranolol or metoprolol did not improve headache frequency. All comparisons were graded as low-quality. Propranolol was more effective than femoxetine, mefenamic acid, naproxen, nifedipine and very low-dose (40mg) nortriptyline, but comparable to 5-hydroxytryptophan, acupuncture, atenolol, behavioral management, biofeedback, candesartan, clonidine, cyclandelate, flunarizine, metoprolol, nadolol, naproxen, nimodipine, riboflavin, timolol, tolfenamic acid, topiramate and valproic acid. All comparisons were single trials and were rated as low-quality evidence with the exception of the comparisons to flunarizine and metoprolol at 8 weeks that were graded as moderate or high-quality. The network meta-analysis confirmed these findings, but suggested that metoprolol was also superior to naproxen (SMD: -1.2, 95% CI: -1.6 to -0.78).

10.1371/journal.pone.0212785.t004

###### Primary outcome (headache frequency) of comparative effectiveness trials.
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  Comparison, Time point                    Weighted Mean Difference (95% CI)   Heterogeneity                    Quality of Evidence
  ----------------------------------------- ----------------------------------- -------------------------------- ---------------------
  **Bisoprolol (5mg)**                      **Bisoprolol (10mg)**                                                
  Baseline                                  0.20 (-0.43 to 0.83)                ---                              Low
  4 Weeks                                   0.0 (-0.74 to 0.74)                 ---                              
  8 weeks                                   0.20 (-0.47 to -0.87)               ---                              
  12 weeks                                  0.0 (-0.67 to -0.67)                ---                              
  **Metoprolol**                            **Acupuncture**                                                      
  17 weeks                                  -0.7 (-2.7 to 1.3)                  ---                              Low
  **Aspirin**                                                                                                    
  8 weeks                                   -1.6 (-2.8 to -0.46)                ---                              Low
  **Bisoprolol**                                                                                                 
  Baseline                                  0.0 (-0.31 to 0.31)                 ---                              Low
  12 weeks                                  -0.09 (-0.62 to 0.44)               ---                              
  **Clomipramine**                                                                                               
  4 weeks                                   -2.0 (-3.9 to -0.16)                ---                              Low
  **Clonidine**                                                                                                  
  Baseline                                  0.00 (-0.51 to 0.51)                ---                              Low
  8 weeks                                   -1.40 (-3.3 to 0.44)                ---                              
  **Flunarizine**                                                                                                
  Baseline                                  -0.60 (-1.4 to 0.19)                ---                              Low
  4 weeks                                   -0.3 (-1.1 to 0.53)                 ---                              
  8 weeks                                   -0.9 (-1.7 to -0.10)                ---                              
  12 weeks                                  -0.5 (-1.3 to 0.33)                 ---                              
  16 weeks                                  -0.1 (-0.93 to 0.73)                ---                              
  20 weeks                                  -0.36 (-1.5 to 0.75)                ---                              
  **Metoprolol + Fluoxetine**                                                                                    
  Baseline                                  -0.03 (-0.40 to 0.33)               ---                              Low
  8 weeks                                   0.30 (0.19 to 0.40)                 ---                              
  **Nebivolol**                                                                                                  
  Baseline                                  0.10 (-0.62 to 0.82)                ---                              Low
  16 weeks                                  -0.30 (-1.2 to 0.60)                ---                              
  **Pizotifen**                                                                                                  
  Baseline                                  0.00 (-0.47 to 0.47)                ---                              Low
  8 weeks                                   0.90 (-0.01 to 1.8)                 ---                              
  **Metoprolol + Flunarizine**              **Flunarizine**                                                      
  12 weeks                                  -0.9 (-1.6 to -0.22)                ---                              Low
  24 weeks                                  -0.8 (-1.6 to -0.04)                ---                              
  36 weeks                                  -0.6 (-2.4 to 1.2)                  ---                              
  48 weeks                                  -0.3 (-1.2 to 0.57)                 ---                              
  **Nadolol (80mg)**                        **Nadolol (160mg)**                                                  
  Baseline                                  0.57 (-2.1 to 3.3)                  ---                              Low
  4 weeks                                   -0.25 (-2.9 to 2.4)                 ---                              
  8 weeks                                   0.11 (-2.6 to 2.8)                  ---                              
  12 weeks                                  -0.34 (-3.1 to 2.4)                 ---                              
  **Pindolol**                              **Pindolol (15mg)**                                                  
  Baseline                                  4.0 (-0.6 to 8.1)                   ---                              Low
  4 weeks                                   4.0 (-0.05 to 8.1)                  ---                              
  **Propranolol**                           **5-Hydroxy-tryptophan**                                             
  Baseline                                  -2.3 (-5.9 to 1.3)                  ---                              Low
  16 weeks                                  -2.9 (-6.6 to 0.81)                 ---                              
  **Acupuncture**                                                                                                
  Baseline                                  -0.10 (-0.59 to 0.40)               ---                              Low
  12 weeks                                  0.30 (-0.25 to 0.85)                ---                              
  **Behavioral Management**                                                                                      
  Baseline                                  -0.40 (-1.1 to 0.34)                ---                              Low
  40 weeks                                  -0.30 (-0.94 to 0.34)               ---                              
  64 weeks                                  -0.20 (-0.89 to 0.49)               ---                              
  **Propranolol + Behavioral Management**                                                                        
  Baseline                                  -0.50 (-1.2 to 0.18)                ---                              Low
  40 weeks                                  0.70 (-.16 to 1.2)                  ---                              
  64 weeks                                  0.80 (0.19 to 1.4)                  ---                              
  **Biofeedback**                                                                                                
  24 weeks                                  0.53 (0.08 to 0.97)                 ---                              Low
  **Candesartan**                                                                                                
  12 weeks                                  -0.04 (-0.59 to 0.51)               ---                              Low
  **Cyclandelate (HA days/mo)**                                                                                  
  Baseline                                  -0.16 (-0.66 to 0.35)               ---                              Low
  4 weeks                                   -0.32 (-0.83 to 0.18)               ---                              
  8 weeks                                   0.13 (-0.37 to 0.63)                ---                              
  **Femoxetine**                                                                                                 
  Baseline                                  0.0 (-2.2 to 2.2)                   ---                              Low
  8 weeks                                   -0.70 (-1.5 to 0.13)                ---                              
  12 weeks                                  -1.5 (-3.6 to 0.55)                 ---                              
  **Flunarizine**                                                                                                
  Baseline                                  -0.005 (-0.11 to 0.10)              Q = 0.83, df = 5, I^2^ = 0.0%    High
  4 weeks                                   0.40 (-0.34 to 1.1)                 Q = 3.1, df = 3, I^2^ = 3.7%     High
  8 weeks                                   0.42 (-0.55 to 1.4)                 Q = 1.48, df = 1, I^2^ = 32.6%   Moderate
  12 weeks                                  0.68 (-0.06 to 1.4)                 Q = 0.55, df = 2, I^2^ = 0.0%    High
  16 weeks                                  -0.04 (-0.19 to 0.12)               Q = 5.44, df = 6, I^2^ = 7.0%    High
  **Mefenamic Acid**                                                                                             
  12 weeks                                  -2.1 (-5.3 to 1.3)                  ---                              Low
  **Metoprolol**                                                                                                 
  Baseline                                  0.00 (-0.38 to 0.38)                ---                              Low
  4 weeks                                   -0.70 (-2.0 to 0.62)                ---                              
  8 weeks                                   0.00 (-0.54 to 0.56)                Q = 0.0, df = 1, I^2^ = 0.0%     
  **Nadolol**                                                                                                    
  Baseline                                  0.27 (-2.6 to 3.2)                  ---                              Low
  4 weeks                                   1.6 (-0.28 to 3.4)                  ---                              
  8 weeks                                   1.7 (-0.23 to 3.6)                  ---                              
  12 weeks                                  1.8 (-0.16 to 3.7)                  ---                              
  24 weeks                                  -4.8 (-8.9 to -0.77)                ---                              
  **Naproxen**                                                                                                   
  12 weeks                                  -1.4 (-1.9 to -0.95)                ---                              Low
  **Nifedipine**                                                                                                 
  Baseline                                  2.5 (1.0 to 3.9)                    ---                              Low
  12 weeks                                  -0.40 (-2.6 to 1.8)                 ---                              
  24 weeks                                  0.70 (-1.5 to 2.9)                  ---                              
  **Nimodipine**                                                                                                 
  Baseline                                  0.20 (-0.86 to 1.2)                 ---                              Low
  4 weeks                                   1.6 (-0.24 to 3.4)                  ---                              
  8 weeks                                   -1.5 (-4.1 to 1.1)                  ---                              
  12 weeks                                  -1.5 (-2.9 to -0.04)                ---                              
  16 weeks                                  -0.30 (-1.7 to 1.1)                 ---                              
  24 weeks                                  -0.01 (-1.3 to 1.3)                 ---                              
  **Propranolol + Flunarizine**                                                                                  
  Baseline                                  -0.14 (-1.8 to 1.5)                 ---                              Low
  16 weeks                                  0.18 (-1.4 to 1.8)                  ---                              
  **Riboflavin**                                                                                                 
  Baseline                                  0.00 (-0.39 to 0.39)                ---                              Low
  4 weeks                                   -0.60 (-0.92 to -0.28)              ---                              
  8 weeks                                   -0.10 (-0.42 to 0.22)               ---                              
  12 weeks                                  0.0 (-0.27 to 0.27)                 ---                              
  24 weeks                                  -0.10 (-0.37 to 0.17)               ---                              
  **Timolol**                                                                                                    
  Baseline                                  0.00 (-0.84 to 0.84)                Q = 0.00, df = 1 I^2^ = 0.0%     Moderate
  12 weeks                                  0.37 (-0.45 to 1.2)                 Q = 0.01, df = 1, I^2^ = 0.0%    
  **Tolfenamic Acid**                                                                                            
  12 weeks                                  0.01 (-0.68 to 0.70)                ---                              Low
  **Topiramate**                                                                                                 
  Baseline                                  -0.02 (-0.35 to 0.31)               Q = 1.47, df = 2 I^2^ = 0.0%     Moderate
  4 weeks                                   -0.19 (-0.76 to 0.39)               Q = 0.18, df = 1 I^2^ = 0.0%     
  8 weeks                                   0.30 (-0.30 to 0.91)                ---                              Low
  12 weeks                                  0.10 (-0.98 to 1.2)                 ---                              
  16 weeks                                  0.30 (-0.94 to 1.5)                 ---                              
  20 weeks                                  0.40 (-0.60 to 1.4)                 ---                              
  24 weeks                                  -0.75 (-1.6 to 0.13)                Q = 4.38, df = 1 I^2^ = 77.2%    
  **Valproic Acid**                                                                                              
  Baseline                                  -0.20 (-1.1 to 0.71)                ---                              Low
  8 weeks                                   -0.16 (-1.7 to 0.75)                ---                              
  **Propranolol + Flunarizine**             **Topiramate**                                                       
  Baseline                                  -0.06 (-0.82 to 0.70)               ---                              Low
  12 weeks                                  0.70 (0.29 to 1.1)                  ---                              
  **Propranolol + Topiramate**              **Topiramate**                                                       
  24 weeks                                  -0.01 (-2.4 to 2.1)                 ---                              Low

10.1371/journal.pone.0212785.t005

###### Secondary outcomes of comparative effectiveness trials.
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  Drug1                                                       Comparison, Time Point                      Weighted Mean Difference (95% CI)   Heterogeneity                    Quality of Evidence
  ----------------------------------------------------------- ------------------------------------------- ----------------------------------- -------------------------------- ---------------------
  **Headache Days Weighted Mean Difference (95% CI)**                                                                                                                          
  **Metoprolol**                                              **Clonidine**                                                                                                    
  Baseline                                                    0.0 (-3.7 to 3.7)                           ---                                 Low                              
  8 Weeks                                                     -1.8 (-5.7 to 2.14)                         ---                                                                  
  **Metoprolol + Fluoxetine**                                                                                                                                                  
  8 weeks                                                     0.83 (0.63 to 1.0)                          ---                                 Low                              
  **Nadolol (80mg)**                                          **Nadolol (160mg)**                                                                                              
  Baseline                                                    2.3 (-3.4 to 7.9)                           ---                                 Low                              
  4 weeks                                                     -0.22 (-5.9 to 5.4)                         ---                                                                  
  8 weeks                                                     -0.05 (-5.9 to 5.8)                         ---                                                                  
  12 weeks                                                    2.2 (-7.9 to 3.6)                           ---                                                                  
  **Pindolol (7.5mg)**                                        **Pindolol (15mg)**                                                                                              
  Baseline                                                    0.05 (-0.94 to 1.0)                         ---                                 Low                              
  4 weeks                                                     0.28 (-0.72 to 1.3)                         ---                                                                  
  **Propranolol**                                             **Acupuncture**                                                                                                  
  Baseline                                                    0.0 (-1.0 to 1.0)                           ---                                 Low                              
  12 weeks                                                    0.70 (-0.43 to 1.8)                         ---                                                                  
  **Atenolol**                                                                                                                                                                 
  8 weeks                                                     0.06 (-1.8 to 1.9)                          ---                                 Low                              
  **Behavioral Management**                                                                                                                                                    
  Baseline                                                    0.50 (-0.88 to 1.9)                         ---                                 Low                              
  40 weeks                                                    -0.10 (-1.3 to 1.1)                         ---                                                                  
  64 weeks                                                    0.10 (-1.1 to 1.3)                          ---                                                                  
  **Candesartan**                                                                                                                                                              
  12 weeks                                                    0.45 (-1.2 to 2.1)                          ---                                 Low                              
  **Clonidine**                                                                                                                                                                
  16 weeks                                                    0.10 (-2.1 to 2.3)                          ---                                 Low                              
  **Cyclandelate**                                                                                                                                                             
  Baseline                                                    -0.60 (-2.5 to 1.3)                         ---                                 Low                              
  4 weeks                                                     -1.1 (-2.8 to 0.64)                         ---                                                                  
  8 weeks                                                     0.40 (-1.2 to 2.0)                          ---                                                                  
  **Femoxetine**                                                                                                                                                               
  8 weeks                                                     -1.6 (-4.5 to 1.3)                          ---                                 Low                              
  **Flunarizine**                                                                                                                                                              
  Baseline                                                    -0.80 (-2.2 to 0.59)                        ---                                 Low                              
  4 weeks                                                     1.4 (0.02 to 2.8)                           ---                                                                  
  8 weeks                                                     0.50 (-0.91 to 1.9)                         ---                                                                  
  12 weeks                                                    -0.5 (-1.9 to 0.96)                         ---                                                                  
  16 weeks                                                    0.61 (-0.91 to 2.1)                         ---                                                                  
  **Metoprolol**                                                                                                                                                               
  Baseline                                                    -0.31 (-1.3 to 0.68)                        ---                                 Low                              
  4 weeks                                                     -0.60 (-4.3 to 3.1)                         ---                                 Low                              
  8 weeks                                                     -0.17 (-0.96 to 0.51)                       Q = 0.73 df = 1, I^2^ = 0.0%        Moderate                         
  16 weeks                                                    0.06 (-1.9 to 2.02)                         ---                                 Low                              
  24 weeks                                                    -2.2 (-4.2 to -0.24)                        ---                                 Low                              
  **Naproxen**                                                                                                                                                                 
  12 weeks                                                    -2.8 (-3.6 to -1.9)                         ---                                 Low                              
  **Nifedipine**                                                                                                                                                               
  Baseline                                                    -0.80 (-3.3 to 1.7)                         ---                                 Low                              
  4 weeks                                                     -3.6 (-7.0 to -0.16)                        ---                                                                  
  16 weeks                                                    -2.2 (-4.0 to -0.32)                        ---                                                                  
  28 weeks                                                    -0.80 (-2.6 to 1.0)                         ---                                                                  
  **Propranolol (80mg v 160mg)**                                                                                                                                               
  Baseline                                                    0.0 (-1.7 to 1.7)                           ---                                 Low                              
  12 weeks                                                    -2.7 (04.9 to -0.5)                         ---                                                                  
  **Tolfenamic Acid**                                                                                                                                                          
  Baseline                                                    0.0 (-1.6 to 1.6)                           ---                                 Low                              
  12 weeks                                                    -0.22 (-2.1 to 1.6)                         ---                                                                  
  **Topiramate**                                                                                                                                                               
  Baseline                                                    0.12 (-0.3 to 0.55)                         ---                                 Low                              
  24 weeks                                                    -0.25 (01.13 to 0.63)                       ---                                                                  
  **Headache Index, Standardized Mean Difference (95% CI)**                                                                                                                    
  **Metoprolol**                                              **Clonidine**                                                                                                    
  Baseline                                                    0.0 (-0.49 to 0.49)                         ---                                 Low                              
  8 Weeks                                                     -0.24 (-0.76 to 0.29)                       ---                                                                  
  **Pindolol (7.5mg)**                                        **Pindolol (15 mg)**                                                                                             
  Baseline                                                    0.05 (-0.94 to 1.04)                        ---                                 Low                              
  4 weeks                                                     0.27 (-0.72 to 1.3)                         ---                                                                  
  **Propranolol**                                             **Amitriptyline**                                                                                                
  Baseline                                                    0.05 (-0.42 to 0.52)                        ---                                 Low                              
  6 weeks                                                     -0.42 (-0.89 to 0.06)                       ---                                                                  
  **Amitriptyline + Biofeedback**                                                                                                                                              
  Baseline                                                    0.08 (-0.37 to 0.53)                        ---                                 Low                              
  6 weeks                                                     -0.24 (-0.69 to 0.21)                       ---                                                                  
  **Amitriptyline + Propranolol**                                                                                                                                              
  Baseline                                                    0.01 (-0.44 to 0.46)                        ---                                 Low                              
  6 weeks                                                     0.06 (-0.39 to 0.51)                        ---                                                                  
  **Amitriptyline + Propranolol + Biofeedback**                                                                                                                                
  Baseline                                                    -0.04 (-0.52 to 0.44)                       ---                                 Low                              
  6 weeks                                                     0.25 (-0.23 to 0.74)                        ---                                                                  
  **Biofeedback**                                                                                                                                                              
  Baseline                                                    0.17 (-0.31 to 0.64)                        ---                                 Low                              
  6 weeks                                                     -0.35 (-0.83 to 0.13)                       ---                                                                  
  **Biofeedback + Propranolol**                                                                                                                                                
  Baseline                                                    -0.03 (-0.50 to 0.44)                       ---                                 Low                              
  6 weeks                                                     0.39 (-0.09 to 0.86)                        ---                                                                  
  **Aspirin**                                                                                                                                                                  
  Baseline                                                    0.00 (-0.65 to 0.65)                        ---                                 Low                              
  6 weeks                                                     0.25 (-0.56 to 1.05)                        ---                                                                  
  **Atenolol**                                                                                                                                                                 
  6 weeks                                                     0.01 (-0.59 to 0.62)                        ---                                 Low                              
  **Femoxetine**                                                                                                                                                               
  Baseline                                                    0.00 (-0.57 to 0.57)                        ---                                 Low                              
  8 weeks                                                     -0.24 (-0.70 to 0.21)                       ---                                                                  
  12 weeks                                                    -0.35 (-0.92 to 0.22)                       ---                                                                  
  **Flunarizine**                                                                                                                                                              
  Baseline                                                    0.12 (-0.17 to 0.42)                        Q = 1.59, df = 2, I^2^ = 0.0%       Moderate                         
  4 weeks                                                     -0.18 (-0.82 to 0.46)                       Q = 2.45, df = 2, I^2^ = 59.3%                                       
  8 weeks                                                     -0.13 (-0.75 to 0.48)                       Q = 2.27, df = 1, I^2^ = 55.9%                                       
  12 weeks                                                    0.16 (-1.1 to 1.4)                          Q = 8.7, df = 1, I^2^ = 88.5%                                        
  16 weeks                                                    -0.08 (-0.48 to 0.32)                       Q = 3.13, df = 2, I^2^ = 49.3%                                       
  **Flunarizine + Propranolol**                                                                                                                                                
  Baseline                                                    0.42 (-0.30 to 1.1)                         ---                                 Low                              
  4 weeks                                                     0.29 (-0.43 to 1.0)                         ---                                                                  
  8 weeks                                                     0.17 (-0.54 to 0.89)                        ---                                                                  
  12 weeks                                                    0.47 (-0.26 to 1.2)                         ---                                                                  
  16 weeks                                                    0.67 (-0.07 to 1.4)                         ---                                                                  
  **Metoprolol**                                                                                                                                                               
  Baseline                                                    0.00 (-0.29 to 0.29)                        Q = 0.00, df = 1, I^2^ = 0.0%       Moderate                         
  8 weeks                                                     0.06 (-0.24 to 0.35)                        Q = 0.23, df = 1, I^2^ = 0.0%                                        
  **Nadolol**                                                                                                                                                                  
  Baseline                                                    0.41 (-0.09 to 0.90)                        ---                                 Low                              
  4 weeks                                                     0.34 (-0.16 to 0.83)                        ---                                                                  
  8 weeks                                                     0.44 (-0.08 to 0.96)                        ---                                                                  
  12 weeks                                                    0.29 (-0.22 to 0.81)                        ---                                                                  
  **Timolol**                                                                                                                                                                  
  Baseline                                                    0.00 (-0.31 to 0.31)                        ---                                 Low                              
  12 weeks                                                    0.17 (-0.14 to 0.48)                        ---                                                                  
  **Valproic Acid**                                                                                                                                                            
  Baseline                                                    -0.09 (-0.56 to 0.38)                                                                                            
  10 weeks                                                    -0.03 (-0.50 to 0.44)                       ---                                 Low                              
  **Propranolol + Flunarizine**                               **Topiramate**                                                                                                   
  Baseline                                                    0.07 (-0.36 to 0.57)                        ---                                 Low                              
  12 weeks                                                    0.99 (0.53 to 1.4)                          ---                                                                  
  **Episodic Migraine, 50% reduction in Headaches**                                                                                                                            
  **Comparison**                                              **RR (95% CI)**                             **Heterogeneity**                   **Quality**                      
  **Metoprolol**                                              **ASA**                                     2.4 (0.88 to 6.7)                   ---                              Low
  **Clonidine**                                               1.3 (0.62 to 2.9)                           ---                                 Low                              
  **Flunarizine**                                             1.1 (0.98 to 1.3)                           ---                                 Low                              
  **Nebivolol**                                               1.1 (0.56 to 2.2)                           ---                                 Low                              
  **Pizotifen**                                               0.69 (0.36 to 1.3)                          ---                                 Low                              
  **Metoprolol + Flunarizine**                                **Flunarizine**                             1.3 (1.0 to 1.6)                    ---                              Low
  **Propranolol**                                             **ASA**                                     1.3 (0.88 to 1.9)                   Q = 2.44, df = 1, I^2^ = 59.1%   Moderate
  **Acupuncture**                                             0.88 (0.57 to 1.3)                          ---                                 Low                              
  **Candesartan**                                             0.93 (0.61 to 1.4)                          ---                                 Low                              
  **Clonidine**                                               1.6 (0.86 to 3.1)                           ---                                 Low                              
  **Cyclandelate**                                            1.0 (0.71 to 1.5)                           Q = 4.39, df = 2, I^2^ = 54.4%      Moderate                         
  **Femoxetine**                                              3.5 (0.43 to 29.4)                          ---                                 Low                              
  **Flunarizine**                                             1.0 (0.89 to 1.2)                           Q = 3.30, df = 5, I^2^ = 0.0%       High                             
  **Flunarizine + Propranolol**                               0.86 (0.59 to 1.2)                          ---                                 Low                              
  **Metoprolol**                                              0.86 (0.60 to 1.2)                          Q = 0.11, df = 1, I^2^ = 0.0%       Moderate                         
  **Nadolol**                                                 0.66 (0.27 to 1.6)                          Q = 6.20, df = 2, I^2^ = 67.8%      Moderate                         
  **Nifedipine**                                              2.2 (1.3 to 3.8)                            ---                                 Low                              
  **Nortriptyline**                                           1.5 (0.54 to 4.2)                           ---                                 Low                              
  **Nortriptyline + Propranolol**                             1.1 (0.48 to 2.7)                           ---                                 Low                              
  **Propranolol (80 vs. 160mg)**                              0.94 (0.72 to 1.2)                          ---                                 Low                              
  **Timolol**                                                 1.1 (0.84 to 1.4)                           ---                                 Low                              
  **Topiramate**                                              1.2 (0.98 to 1.4)                           Q = 0.05, df = 2 I^2^ = 0.0%        Moderate                         
  **Valproic Acid**                                           0.96 (0.77 to 1.2)                          Q = 0.16, df = 2, I^2^ = 0.0%       Moderate                         
  **Propranolol + Amitriptyline**                             **Amitriptyline**                           1.02 (0.92 to 1.1)                  ---                              Low
  **Propranolol + Flunarizine**                               **Nimodipine + Diazepam + Oryzanol**        1.5 (1.2 to 2.0)                    ---                              Low
  **Propranolol + Nadolol**                                   **Behavioral Management**                   0.98 (0.58 to 1.7)                  ---                              Low
  **Propranolol + Nadolol**                                   **Behavioral Management + Propranolol**     0.44 (0.30 to 0.66)                 ---                              Low
  **Medicine Use (doses/month)**                                                                                                                                               
  **Comparison**                                              **Weighted Mean Difference (95% CI)**       **Heterogeneity**                   **Quality of evidence**          
  **Metoprolol**                                              **Bisoprolol**                                                                                                   
  Baseline                                                    0.0 (-0.31 to 0.31)                         ---                                 Low                              
  12 weeks                                                    0.01 (-0.30 to 0.32)                        ---                                                                  
  **Clomipramine**                                                                                                                                                             
  4 weeks                                                     -0.55 (-1.2 to 0.08)                        ---                                 Low                              
  **Clonidine**                                                                                                                                                                
                                                              Baseline                                    0.0 (-0.50 to 0.50)                 ---                              Low
                                                              8 weeks                                     -0.52 (-1.0 to 0.02)                ---                              
  **Propranolol**                                             **5-Hydroxytryptophan**                                                                                          
  Baseline                                                    0.48 (-0.16 to 1.1)                         ---                                 Low                              
  16 weeks                                                    0.22 (-0.41 to 0.85)                        ---                                                                  
  **Candesartan**                                                                                                                                                              
  12 weeks                                                    -0.45 (-0.82 to -0.09)                      ---                                 Low                              
  **Cyclandelate**                                                                                                                                                             
  Baseline                                                    -0.49 (-1.0 to 0.02)                        ---                                 Low                              
  4 weeks                                                     -0.70 (-1.2 to -0.19)                       ---                                                                  
  8 weeks                                                     -0.19 (-0.69 to 0.32)                       ---                                                                  
  **Femoxetine**                                                                                                                                                               
  Baseline                                                    0.00 (-0.57 to -0.57)                       ---                                 Low                              
  12 weeks                                                    -0.83 (-1.4 to -0.24)                       ---                                                                  
  **Flunarizine**                                                                                                                                                              
  Baseline                                                    0.08 (-0.10 to 0.26)                        Q = 1.98, df = 2, I^2^ = 0.0%       Moderate                         
  4 weeks                                                     -.44 (0.02 to 0.86)                         ---                                 Low                              
  8 weeks                                                     -0.15 (-0.57 to 0.28)                       ---                                 Low                              
  12 weeks                                                    -0.23 (-0.43 to -0.04)                      Q = 0.06, df = 1, I^2^ = 0.0%       Moderate                         
  16 weeks                                                    -0.07 (-0.41 to 0.27)                       Q = 0.01, df = 1, I^2^ = 0.0%       Moderate                         
  **Metoprolol**                                                                                                                                                               
  Baseline                                                    0.00 (-0.29 to 0.29)                        Q = 0.00, df = 1, I^2^ = 0.0%       Moderate                         
  8 weeks                                                     -0.19 (-0.49 to 0.11)                       Q = 1.00, df = 1, I^2^ = 0.5%                                        
  **Nadolo**l                                                                                                                                                                  
  Baseline                                                    -0.31 (-1.1 to 0.45)                        ---                                 Low                              
  24 weeks                                                    -0.73 (-1.5 to 0.05)                        ---                                                                  
  **Health Related Quality of Life**                                                                                                                                           
  **Comparison**                                              **Standardized Mean Difference (95% CI)**   **Heterogeneity**                   **Quality of evidence**          
  **Metoprolol**                                              **Nebivolol** (MOS SF36)                                                                                         
                                                              Baseline                                    -0.21 (-0.93 to 0.51)               ---                              Low
                                                              16 Weeks                                    -0.46 (-1.2 to 0.27)                ---                              
  **Propranolol**                                             **Acupuncture** (MOS SF36)                                                                                       
  Baseline                                                    -0.19 (-0.56 to 0.19)                       ---                                 Low                              
  12 weeks                                                    -0.47 (-0.84 to -0.10)                      ---                                                                  
  **Behavioral Management**                                                                                                                                                    
  Baseline                                                    0.14 (-0.24 to 0.52)                        ---                                 Low                              
  40 weeks                                                    0.48 (0.10 to 0.86)                         ---                                                                  
  64 weeks                                                    0.23 (-0.15 to 0.60)                        ---                                                                  
  **Behavioral Management + Propranolol**                                                                                                                                      
  Baseline                                                    0.07 (-0.28 to 0.43)                        ---                                 Low                              
  40 weeks                                                    0.68 (0.31 to 1.0)                          ---                                                                  
  64 weeks                                                    0.61 (-.24 to 0.97)                         ---                                                                  
  **Candesartan**                                                                                                                                                              
  12 weeks                                                    -0.18 (-0.54 to 0.19)                       ---                                 Low                              
  **Riboflavin** (MIDAS)                                                                                                                                                       
  Baseline                                                    -0.06 (-0.46 to 0.33)                       ---                                 Low                              
  4 weeks                                                     0.00 (-0.39 to 0.39)                        ---                                                                  
  **Propranolol + Topiramate**                                **Topiramate** (MIDAS)                                                                                           
  24 weeks                                                    0.01 (-0.39 to 0.41)                        ---                                 Low                              
  **Headache Severity**                                                                                                                                                        
  **Comparison**                                              **Standardized Mean Difference (95% CI)**   **Heterogeneity**                   **Quality of evidence**          
  **Metoprolol**                                              **Aspirin**                                                                                                      
  8 weeks                                                     0.33 (-0.20 to 0.86)                        ---                                 Low                              
  **Acupuncture**                                                                                                                                                              
  17 weeks                                                    -0.46 (-0.91 to -0.002)                     ---                                 Low                              
  **Bisoprolol**                                                                                                                                                               
  Baseline                                                    0.00 (-0.31 to 0.31)                        ---                                 Low                              
  12 weeks                                                    0.19 (-0.13 to 0.3)                         ---                                                                  
  **Flunarizine**                                                                                                                                                              
  Baseline                                                    0.46 (0.14 to 0.79)                         ---                                 Low                              
  4 weeks                                                     0.13 (-0.22 to 0.48)                        ---                                                                  
  8 weeks                                                     0.38 (0.02 to 0.73)                         ---                                                                  
  12 weeks                                                    0.13 (-0.22 to 0.48)                        ---                                                                  
  16 weeks                                                    0.75 (0.39 to 1.1)                          ---                                                                  
  20 weeks                                                    0.42 (0.07 to 0.77)                         ---                                                                  
  **Nebivolol**                                                                                                                                                                
  16 weeks                                                    0.19 (-0.53 to 0.91)                        ---                                 Low                              
  **Pizotifen**                                                                                                                                                                
  Baseline                                                    0.00 (-0.47 to 0.47)                        ---                                 Low                              
  8 weeks                                                     -0.91 (-1.4 to -0.40)                       ---                                                                  
  **Metoprolol + Flunarizine**                                **Flunarizine**                                                                                                  
  12 weeks                                                    -0.25 (-0.79 to 0.26)                       ---                                 Low                              
  24 weeks                                                    -0.55 (-1.1 to -0.02)                       ---                                                                  
  36 weeks                                                    -0.49 (-1.0 to 0.047)                       ---                                                                  
  48 weeks                                                    -0.54 (-0.72 to -0.19)                      ---                                                                  
  **Propranolol**                                             **Acupuncture**                                                                                                  
  Baseline                                                    0.26 (-0.13 to 0.65                         ---                                 Low                              
  12 weeks                                                    0.63 (0.23 to 1.03)                         ---                                                                  
  **5-hydroxytryptophan**                                                                                                                                                      
  Baseline                                                    0.18 (-0.45 to 0.81)                        ---                                 Low                              
  16 weeks                                                    0.00 (-0.63 to 0.63)                        ---                                                                  
  **Biofeedback**                                                                                                                                                              
  Baseline                                                    -0.07 (-0.36 to 0.21)                       ---                                 Low                              
  24 weeks                                                    0.13 (-0.15 to 0.42)                        ---                                                                  
  **Cyclandelate**                                                                                                                                                             
  Baseline                                                    -0.07 (-0.58 to 0.43)                       ---                                 Low                              
  4 weeks                                                     -0.17 (-0.68 to 0.33)                       ---                                                                  
  8 weeks                                                     -0.01 (-0.51 to 0.48)                       ---                                                                  
  **Flunarizine**                                                                                                                                                              
  Baseline                                                    0.00 (-0.32 to 0.32)                        Q = 0.0, df = 1, I^2^ = 0.0%        Moderate                         
  4 weeks                                                     -0.24 (-0.66 to 0.17)                       ---                                 Low                              
  8 weeks                                                     -0.57 (-1.0 to -0.13)                       ---                                 Low                              
  12 weeks                                                    -0.25 (-0.69 to 0.19)                       ---                                 Low                              
  16 weeks                                                    0.17 (-0.52 to 0.85)                        Q = 79.7, df = 3, I^2^ = 92.9%      High                             
  **Metoprolol**                                                                                                                                                               
  Baseline                                                    0.0 (-0.37 to 0.37)                         ---                                 Low                              
  8 weeks                                                     0.0 (-0.38 to 0.38)                         ---                                                                  
  **Nadolol**                                                                                                                                                                  
  Baseline                                                    0.00 (-0.67 to 0.84)                        ---                                 Low                              
  24 Weeks                                                    0.86 (0.07 to 1.7)                          ---                                                                  
  **Naproxen**                                                                                                                                                                 
  12 weeks                                                    0.14 (-0.29 to 0.56)                        ---                                 Low                              
  **Nimodipine**                                                                                                                                                               
  24 weeks                                                    -0.50 (-0.89 to -0.11)                      ---                                 Low                              
  **Propranolol (80 v 160mg doses)**                                                                                                                                           
  Baseline                                                    0.00 (-0.40 to 0.40)                        ---                                 Low                              
  8 weeks                                                     0.00 (-0.51 to 0.51)                        ---                                                                  
  12 weeks                                                    0.00 (-0.43 to 0.43)                        ---                                                                  
  **Riboflavin**                                                                                                                                                               
  Baseline                                                    0.32 (-0.08 to 0.71)                        ---                                 Low                              
  4 weeks                                                     0.33 (-0.07 to 0.72)                        ---                                                                  
  8 weeks                                                     0.21 (-0.18 to 0.60)                        ---                                                                  
  12 weeks                                                    0.42 (0.02 to 0.82)                         ---                                                                  
  24 weeks                                                    0.11 (-0.29 to 0.50)                        ---                                                                  
  **Timolol**                                                                                                                                                                  
  Baseline                                                    0.00 (-0.31 to 0.31)                        ---                                 Low                              
  12 weeks                                                    0.14 (-0.17 to 0.45)                        ---                                                                  
  **Tolfenamic Acid**                                                                                                                                                          
  Baseline                                                    0.26 (-0.37 to 0.68)                        ---                                 Low                              
  12 weeks                                                    0.15 (-0.63 to 0.93)                        Q = 4.53, df = 1, I^2^ = 77.8%      Moderate                         
  **Topiramate**                                                                                                                                                               
  Baseline                                                    -0.44 (-0.95 to 0.07)                       ---                                 Low                              
  4 weeks                                                     -0.19 (-0.69 to 0.32)                       ---                                                                  
  8 weeks                                                     0.23 (-0.28 to 0.74)                        ---                                                                  
  **Headache Duration**                                                                                                                                                        
  **Comparison**                                              **Weighted Mean Difference (95% CI)**       **Heterogeneity**                   **Quality of evidence**          
  **Bisoprolol (5mg)**                                        **Bisoprolol (10 mg)**                                                                                           
  Baseline                                                    2.4 (-4.3 to 9.1)                           ---                                 Low                              
  12 weeks                                                    -4.8 (-9.9 to 0.31)                         ---                                                                  
  **Metoprolol**                                              **Acupuncture**                                                                                                  
  12 weeks                                                    -2.4 (-6.5 to 1.7)                          ---                                 Low                              
  **Bisoprolol**                                                                                                                                                               
  Baseline                                                    0.0 (-4.9 to 4.9)                           ---                                 Low                              
  12 weeks                                                    0.30 (-4.2 to 4.8)                          ---                                                                  
  **Clomipramine**                                                                                                                                                             
  4 weeks                                                     -2.8 (-4.4 to -1.2)                         ---                                 Low                              
  **Flunarizine**                                                                                                                                                              
  Baseline                                                    -1.3 (-3.7 to 1.1)                          ---                                 Low                              
  4 weeks                                                     -3.2 (-5.7 to -0.69)                        ---                                                                  
  8 weeks                                                     -3.3 (-5.9 to -0.66)                        ---                                                                  
  12 weeks                                                    -2.4 (-4.9 to 0.11)                         ---                                                                  
  16 weeks                                                    -0.40 (-3.2 to 2.4)                         ---                                                                  
  20 weeks                                                    -1.3 (-4.1 to 1.5)                          ---                                                                  
  **Metoprolol + Fluoxetine**                                                                                                                                                  
  Baseline                                                    0.10 (-0.15 to 0.35)                        ---                                 Low                              
  12 weeks                                                    -0.53 (-0.75 to -0.31)                      ---                                                                  
  **Nebivolol**                                                                                                                                                                
  16 weeks                                                    11 (-18.6 to 40.6)                          ---                                 Low                              
  **Nifedipine**                                                                                                                                                               
  Baseline                                                    1.0 (-14.3 to 16.3)                         ---                                 Low                              
  4 weeks                                                     15.8 (0.49 to 31.1)                         ---                                                                  
  28 weeks                                                    12.2 (0.66 to 23.7)                         ---                                                                  
  **Pindolol (7.5 mg)**                                       **Pindolol (15 mg)**                                                                                             
  Baseline                                                    -0.70 (-7.9 to 6.6)                         ---                                 Low                              
  4 weeks                                                     -0.80 (-8.2 to 6.5)                         ---                                                                  
  **Propranolol**                                             **5-hydroxytryptophan**                                                                                          
  Baseline                                                    6.1 (-1.1 to 13.3)                          ---                                 Low                              
  16 weeks                                                    3.6 (-3.7 to 10.9)                          ---                                                                  
  **Biofeedback**                                                                                                                                                              
  Baseline                                                    0.04 (-2.5 to 2.6)                          ---                                 Low                              
  24 weeks                                                    0.33 (-1.3 to 2.0)                          ---                                                                  
  **Candesartan**                                                                                                                                                              
  12 weeks                                                    6.3 (-1.9 to 14.5)                          ---                                 Low                              
  **Cyclandelate**                                                                                                                                                             
  Baseline                                                    6.7 (-22.5 to 9.1)                          ---                                 Low                              
  4 weeks                                                     -12.6 (-37.4 to 12.2)                       ---                                                                  
  8 weeks                                                     6.6 (-18.2 to 31.4)                         ---                                                                  
  12 weeks                                                    -4.5 (-26.6 to 17.6)                        ---                                                                  
  **Flunarizine**                                                                                                                                                              
  Baseline                                                    2.7 (-1.2 to 6.6)                           ---                                 Low                              
  4 weeks                                                     -0.55 (-4.8 to 3.7)                         Q = 0.06, df = 1, I^2^ = 0.0%       Moderate                         
  8 weeks                                                     0.29 (-3.3 to 3.9)                          Q = 0.08, df = 1, I^2^ = 0.0%       Moderate                         
  12 weeks                                                    -0.21 (-3.3 to 2.9)                         Q = 0.09, df = 1, I^2^ = 0.0%       Moderate                         
  16 weeks                                                    1.4 (0.23 to 2.6)                           Q = 4.33, df = 4, I^2^ = 7.6%       High                             
  **Mefenamic Acid**                                                                                                                                                           
  12 weeks                                                    7.0 (-27.3 to 41.3)                         ---                                 Low                              
  **Metoprolol**                                                                                                                                                               
  Baseline                                                    -24.0 (-40.3 to -7.7)                       ---                                 Low                              
  4 weeks                                                     4.2 (-12.1 to 20.5)                         ---                                                                  
  16 weeks                                                    0.0 (-12.3 to 12.3)                         ---                                                                  
  28 weeks                                                    33.0 (6.3 to 59.7)                          ---                                                                  
  **Nadolo**l                                                                                                                                                                  
  Baseline                                                    -8.1 (-11.4 to -4.8)                        ---                                 Low                              
  24 weeks                                                    -19.5 (-31.8 to -7.1)                       ---                                                                  
  **Nifedipine**                                                                                                                                                               
  Baseline                                                    -1.0 (-16.3 to 14.3)                        ---                                 Low                              
  4 weeks                                                     -15.8 (-31.1 to -0.49)                      ---                                                                  
  16 weeks                                                    -12.2 (-23.7 to -0.66)                      ---                                                                  
  28 weeks                                                    20.0 (0.97 to 39.0)                         ---                                                                  
  **Nimodipine**                                                                                                                                                               
  24 weeks                                                    -4.0 (-7.9 to -0.08)                        ---                                 Low                              
  **Propranolol (80 mg vs 160mg)**                                                                                                                                             
  Baseline                                                    0.0 (-1.2 to 1.2)                           ---                                 Low                              
  8 weeks                                                     -0.30 (-6.9 to 6.3)                         ---                                                                  
  12 weeks                                                    0.20 (-1.8 to 2.2)                          ---                                                                  
  **Riboflavin**                                                                                                                                                               
  Baseline                                                    0.10 (-0.29 to 0.49)                        ---                                 Low                              
  4 weeks                                                     0.10 (-0.31 to 0.51)                        ---                                                                  
  8 weeks                                                     0.00 (-0.26 to 0.26)                        ---                                                                  
  12 weeks                                                    -0.10 (-0.39 to 0.19)                       ---                                                                  
  24 weeks                                                    0.30 (-0.06 to 6.6)                         ---                                                                  
  **Timolol**                                                                                                                                                                  
  Baseline                                                    0.00 (-2.6 to 2.6)                          ---                                 Low                              
  12 weeks                                                    -0.03 (-2.3 to 2.3)                         ---                                                                  
  **Tolfenamic Acid**                                                                                                                                                          
  Baseline                                                    6.4 (-21.9 to 34.7)                         ---                                 Low                              
  12 weeks                                                    1.7 (-4.6 to 8.0)                           Q = 0.05, df = 1, I^2^-0.0%         Moderate                         
  **Topiramate**                                                                                                                                                               
  Baseline                                                    -1.3 (-4.8 to 2.3)                          ---                                 Low                              
  4 weeks                                                     -1.2 (-4.6 to 2.3)                          ---                                                                  
  8 weeks                                                     1.0 (-1.9 to 4.0)                           ---                                                                  
  **Valproic Acid**                                                                                                                                                            
  Baseline                                                    -1.4 (-9.9 to 7.2)                          ---                                 Low                              
  10 weeks                                                    -0.70 (-4.0 to 2.6)                         ---                                                                  

Chronic migraine {#sec012}
----------------

There were four trials that evaluated beta-blockers for chronic migraine headaches, none were placebo controlled. ([Table 6](#pone.0212785.t006){ref-type="table"}). Propranolol was compared to flunarizine \[[@pone.0212785.ref151]\], nortriptyline \[[@pone.0212785.ref076]\], valproic acid \[[@pone.0212785.ref105]\] and to the combination of propranolol and flunarizine \[[@pone.0212785.ref151]\]. In addition, a combination of propranolol and topiramate was compared to topiramate alone \[[@pone.0212785.ref129]\]. Propranolol was no better than valproic acid or flunarizine and the combinations (propranolol + topiramate and propranolol + flunarizine) was no better than topiramate and flunarizine alone ([Table 6](#pone.0212785.t006){ref-type="table"}).

10.1371/journal.pone.0212785.t006

###### Non-episodic trials.

![](pone.0212785.t006){#pone.0212785.t006g}

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Chronic Migraine                                                                                                                        
  -------------------------------------------- -------------------------------------- ---------------------- ---------------------- ----- -----
  Propranolol v. Placebo                       50% reduction in headache (RR)         42 weeks               2.0 (0.94 to 4.3)      ---   Low

  Propranolol v. Flunarizine                   Headache Frequency (headaches/month)   Baseline               3.0 (0.79 to 5.2)      ---   Low

  8 weeks                                      1.0 (-1.5 to 3.5)                      ---                                                 

  Propranolol + Flunarizine vs. Flunarizine    Headache Frequency (headaches/month)   Baseline               2.0 (-0.19 to 4.2)     ---   Low

  8 weeks                                      3.0 (0.56 to 5.4)                      ---                                                 

  50% reduction in headache (RR)               8 weeks                                1.3 (0.97 to 1.6)      ---                    Low   

  Propranolol v. Nortriptyline                 Headache Frequency (Headaches/month)   Baseline               -1.0 (-4.7 to 2.7)     ---   Low

  8 weeks                                      -9.0 (-12.7 to -5.3)                   ---                                                 

  Propranolol v. Propranolol + Nortriptyline   Headache Frequency (Headaches/month)   Baseline               -4.0 (-7.8 to -0.24)   ---   Low

  8 weeks                                      -7.0 (-10.8 to -3.3)                   ---                                                 

  Propranolol + Topiramate v. Topiramate       Headache Frequency (headaches/month)   Baseline               0.0 (-0.28 to 0.28)    ---   Low

  12 weeks                                     -0.80 (-2.3 to 0.67)                   ---                                                 

  Health Related Quality of Life (MIDAS)       Baseline                               0.00 (-0.28 to 0.28)   ---                    Low   

  12 weeks                                     0.09 (-0.26 to 0.44)                   ---                                                 

  50% reduction in headache (RR)               12 weeks                               1.05 (0.63 to 1.7)     ---                    Low   

  24 weeks                                     1.1 (0.79 to 1.8)                      ---                                                 

  Propranolol v. Valproic Acid                 Headache Frequency (headaches/month)   8 weeks                4.8 (0.27 to 9.2)      ---   Low

  **Chronic Tension-Type Headache**                                                                                                       

  Pindolol + Amitriptyline v. Placebo          Headache Frequency (headaches/month)   Baseline               1.4 (-2.3 to 5.0)      ---   Low

  4 weeks                                      7.8 (-13.9 to -1.5)                    ---                                                 

  8 weeks                                      -11.6 (-16.8 to -5.5)                  ---                                                 

  50% reduction in headache (RR)               8 weeks                                3.8 (1.5 to 9.3)       ---                    Low   

  Headache Severity (SMD)                      Baseline                               0.29 (-0.34 to 0.91)   ---                    Low   

  8 weeks                                      -0.68 (-1.3 to -0.04)                  ---                                                 

  Pindolol + Amitriptyline v. Amitriptyline    Headache Frequency (headaches/month)   Baseline               1.6 (-2.2 to 5.3)      ---   Low

  4 weeks                                      0.64 (-5.2 to 6.4)                     ---                                                 

  8 weeks                                      -1.2 (-6.4 to 4.1)                     ---                                                 

  50% reduction in headache (RR)               8 weeks                                1.4 (0.87 to 2.2)      ---                    Low   

  Headache Severity (SMD)                      Baseline                               3.7 (2.7 to 4.7)       ---\                   Low   
                                                                                                             ---                          

  8 weeks                                      -0.05 (-0.65 to 0.56)                  ---                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------

Tension-type headache {#sec013}
---------------------

There was only one trial evaluating tension-type headache, comparing the combination of pindolol and amitriptyline to placebo and to amitriptyline alone \[[@pone.0212785.ref057]\]. The combination of pindolol and amitriptyline was more effective than placebo at reducing headache frequency at 4 and 8 weeks ([Table 6](#pone.0212785.t006){ref-type="table"}) and in reducing headaches by at least 50% (RR: 3.8, 95% CI: 1.5--9.3), but equally effective with amitriptyline.

Adverse events {#sec014}
--------------

Participants on beta-blockers were more likely to experience side effects than those on placebo (RR: 1.2, 95% CI: 1.0--1.4), though they were not more likely to withdraw (RR: 0.99, 95% CI: 0.83 to 1.2). Specific side effects more common with beta-blockers included dizziness (RR: 1.5, 95% CI: 1.0--2.3) and fatigue (RR: 1.5, 95% CI: 1.2--2.0). Depression, gastrointestinal problems, paresthesia's and weight gain were not significantly different than placebo.

Propranolol was the only beta-blocker with sufficient numbers of studies to perform sensitivity analysis. There was no evidence of publication bias for propranolol's reduction of headache frequency at 8 weeks (Egger's p = 0.77) or at 12 weeks (p = 0.62). There was no evidence of an effect of quality (p = 0.97), age (p = 0.71), percent women (p = 0.28), percentage of dropouts (p = 0.55), dose (p = 0.61), intention to treat analysis (p = 0.35), concealed allocation (p = 0.38) or appropriateness of blinding (p = 0.98).

Discussion {#sec015}
==========

This review included one hundred and eight randomized controlled trials. Nearly all evaluated the efficacy of beta-blockers for episodic migraine headaches. Compared to placebo, propranolol was effective in reducing episodic migraine frequency. The effect began as early as four weeks. Migraine headache sufferers experienced an average reduction of 1.3 headaches/month; this translates to a reduction from 4.8 to 3.5 headaches a month. Subjects given propranolol were more likely to report at least 50% reduction in headaches and to reduce their consumption of analgesic medications. In addition to reducing the number of headaches, the residual headaches were less severe and shorter in duration compared to those receiving placebo. Outcomes from the propranolol comparisons to placebo were rated as high-quality evidence. In three trials, metoprolol also reduced headache frequency, though the reduction was less than 1 headache a month. Conclusions regarding the efficacy of other beta-blockers is less certain, as most were studied in just one trial each. Atenolol, bisoprolol and timolol had weak evidence of benefit. Acebutolol, alprenolol and nadolol appeared to be ineffective in migraine prophylaxis. This is unlikely to be due to properties of the beta-blockers. Propranolol is nonselective as is alprenolol and nadolol. Metoprolol, also effective is a ß-1 selective drug as is atenolol, bisoprolol and acebutolol. Given that acebutolol, alprenolol and nadolol were only studied in one trial each, it is possible that this may be either random variation in outcomes or a problem with the trials (such as dose or duration). The network analysis suggests that the benefit of beta-blocker may be a class effect.

The literature comparing beta-blockers to other modalities consisted mostly of single-trials with the exception of the comparison of propranolol to metoprolol (moderate quality, no difference) and to flunarizine (high quality, no difference). Flunarizine, not available in the United States, is well-established as effective in treating migraine headache. Universally, beta-blockers were associated with bradycardia and with lower average pulse rates than placebo trials. This is not surprising given their impact on chronotropy. Other side effects more common among participants taking beta-blockers included dizziness and fatigue, though subjects on beta-blockers were not more likely to withdraw from the studies.

While these conclusions are similar to previous reviews, this analysis is a unique contribution in many ways, first it included many more trials than previously reported, including Chinese trials that had previously not been included. Secondly, all beta-blockers were carefully parsed by type of headache (tension v. migraine, episodic v. chronic). Third, this study examined outcomes at the specific times reported, it is common for meta-analyses to pool trials at the last time point, regardless of whether there were significant differences in that time-point. Fourth, trial sequential analysis that demonstrated the adequacy of the current database for propranolol, suggesting that there is low likelihood of type 1 error in the conclusions. Fifth, the network meta-analysis didn't show clear benefit of one beta-blocker over another, suggesting a class effect, though other beta-blockers have weaker evidence for benefit.

An important question, unanswered in this review, is how effective beta-blockers are compared to other commonly used prophylactic regimens. Propranolol, metoprolol and flunarizine appear to have similar efficacy. The other comparisons were all single-trial comparisons, making definitive conclusions impossible. In a previous review, tricyclic antidepressants resulted in a reduction in headache frequency for patients experiencing chronic migraines of 1.3 SMD, compared to placebo, a large effect \[[@pone.0212785.ref017]\]. In this study, there was only had one trial on chronic migraines, and the calculated SMD was 0.58, about half of the effect previously reported for TCAs. In a network meta-analysis of chronic migraines, tricyclic antidepressants were more effective than propranolol \[[@pone.0212785.ref017]\] but propranolol was similar in efficacy to antiepileptics and flunarizine, similar to findings in this study, though it is important to note that the majority of trials for beta-blockers are for episodic rather than chronic migraines. Definitive answer to this comparative effectiveness question requires additional studies that directly compare the different prophylactic modalities.

This review has several important limitations. First, while the quality of evidence for the comparison between propranolol and placebo was high, in general, the remaining comparisons were of low quality, consisting mostly of underpowered single randomized trials. While all the included trials were randomized, there were significant methodologic problems; combining poorly designed studies can lead to questionable results. It is important to note that most of the comparisons were graded as being of low-quality evidence because of the paucity of studies and concern about study problems. Secondly, studies were inconsistent in reporting outcomes, so even when there were more than one trial available, specific outcomes may only be provided by a single study. Moreover, there were significant problems with selective reporting of outcomes and many studies did not collect information on headache frequency, the measure preferred by the International Headache Society. Third, the number of studies available precluded sensitivity analyses, such as assessing for publication bias or exploring sources of heterogeneity. Fourth, beta-blockers have been studied almost exclusively in the management of episodic migraine headaches. Their benefit for chronic episodic or tension-type headaches is uncertain. Fifth, because of the paucity of trials for most beta-blockers the network analysis was underpowered to show differences between beta-blockers, Sixth, the average age of participants was 38, and mostly female. While this reflects the demographics of headache, it limits applicability to older adults.

Conclusions {#sec016}
===========

Propranolol is effective in reducing the burden of patients with episodic migraine headaches, reducing headaches from 5 to 3 headaches a month. This means that migraine sufferers given propranolol will have substantial residual headache burden. Propranolol reduces headaches by more than 50% as well as reducing the number of analgesic medication doses required. It also reduces the severity or duration of the headaches experienced. Propranolol and metoprolol exert similar effects and propranolol is as effective as flunarizine. The data for other beta-blockers and other comparisons are less clear.
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